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ABSTRACT
Thymidine Kinase 1: Diagnostic and Prognostic Significance in Malignancy
Melissa Alegre
Department of Microbiology and Molecular Biology, BYU
Doctor of Philosophy
Thymidine kinase 1 (TK1) is a cancer biomarker which has diagnostic and prognostic
potential in a variety of malignancies. TK1 is significantly elevated in the serum and tumor tissue
of most malignancies. This increase in TK1 can be detected in the very early stages of
malignancy, including in pre-malignant disease with an increased risk for progression. Several
studies have demonstrated that elevated TK1 is found in serum months before any clinical
symptoms of malignancy. It has also been demonstrated that TK1 is elevated months before
clinical recurrence of malignancy.
This work first sought to demonstrate the early nature of TK1 expression in breast tumor
tissue and pre-malignant tissue. We found that TK1 is elevated in breast hyperplasia tissue and
breast carcinoma tissue. In this study we also identified some cases of ‘normal’ tumor margins
(considered normal by current pathological standards) which also had elevated TK1 expression.
Conversely, true normal breast tissue from noncancerous individuals had no reported elevation in
TK1 expression. This study illustrated that TK1 is elevated in pre-malignant breast hyperplasia
tissue, as well as some ‘normal’ tumor margins. TK1 expression was significantly elevated in
lung, prostate, colon, esophagus, stomach, liver, and kidney tissues. This work further
investigated TK1 expression in a variety of malignant tissue including the two leading causes of
cancer mortality in men: lung and prostate cancer. In our study, TK1 was significantly elevated
in lung and prostate cancer but not significantly elevated in prostate hyperplasia tissue. TK1
expression also increased with increasing grade in prostate carcinoma tissue. Overall, this work
demonstrated that TK1 is a good universal marker of malignancy and is elevated in early cancer
development.
Despite the potential for TK1 as both a screening and monitoring treatment tool, there
have been significant challenges associated with developing a clinically relevant method of TK1
detection. This work proposes one clinically relevant method of detection, namely a TK1 ELISA.
Using preoperable lung cancer patients and normal controls, we developed a sensitive and
specific ELISA which shows highly statistically significant differences in serum TK1 levels
between stage 1 and stage 2 lung cancer compared with normal controls. In fact, this TK1 ELISA
is more sensitive and accurate than the traditional TK radioassay, which was unable to detect
differences in TK1 between early stage lung cancer and normal patients. Although elevated TK1
is not lung cancer specific, we reported significantly elevated TK1 levels in lung cancer sputum.
Screening of sputum and serum for TK1 may be one method for the early detection of lung
cancer.
Overall, we report TK1 has promising diagnostic potential in a variety of malignancies.
We also propose one sensitive and specific method to detect TK1 levels which may easily be
adapted to meet current clinical applications. We hope this work will help propel TK1 forward
into clinical view in the coming years.
Keywords: Thymidine Kinase 1, lung cancer, proliferation marker, ELISA
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Introduction: The Clinical Significance and Biology of Thymidine Kinase 1
Melissa M. Alegre, Richard A. Robison, Kim L. O’Neill
Citation: Alegre, M. M., Robison, R. A., & O'Neill, K. L. (under review). The Clinical Significance and Biology of
Thymidine Kinase 1.Oncology: iConcept Press.
Abstract: Cancer is a complex disease in which there is still a demand for clinically relevant biomarkers.
Thymidine Kinase 1 (TK1) is one cancer biomarker which has value both in early detection and monitoring
treatment responsiveness. TK1 is primarily responsible for maintaining thymidine nucleotide pools by converting dT
to dTMP. In malignancy, TK1 plays a crucial role in DNA damage helping cancer cells to repair themselves
following chemotherapeutic treatment, a potential mechanism of resistance. The structure of TK1 is essential to its
function and regulation in malignancy. A thorough understanding of these aspects helps to explain the challenges
associated with TK1’s detection and its transition into the clinic. In malignancy, TK1 is elevated in both the serum
and tumor tissue. This is true for a wide variety of malignancies including both haematological and solid tumors.
Typically its elevation is correlated to stage and grade of a tumor. High levels of TK1 are indicative of a worse
prognosis and greater risk of recurrence. In fact, numerous studies have revealed that serum-TK1 levels are elevated
months before a patient exhibits clinical relapse. In comparison studies with other proliferation markers and other
serum biomarkers, TK1 appears to be more accurate and sensitive. Additionally, TK1 has therapeutic potential and
has begun to be used as an imaging tool for positron emission tomography (PET). As TK1 is propelled into clinical
view, it becomes more essential to understand the basic biology and clinical advances associated with this promising
biomarker. This review seeks to highlight these important advances to help propagate a wide-spread understanding
of TK1.

1 Introduction
Cancer is a complex disease and remains the second leading cause of death overall (Siegel et al., 2013). Our
knowledge of the biochemical pathways that contribute to malignancy is ever increasing. As we understand
more cancer biology, we also identify relevant clinical indicators of malignancy called biomarkers. One class
of biomarkers of particular note have been proliferation markers including thymidine kinase 1 (TK1), Ki-67,
and proliferating cell nuclear antigen (PCNA). Ki-67 is the most prominent and widely used proliferation
marker, although its relevance is limited to immunohistochemical assessment (Dowsett et al., 2011). However,
recent evidence indicates that TK1may be a more accurate proliferation marker than either Ki-67 or PCNA in
non-small cell, breast, and colorectal carcinomas (Q. He et al., 2004; Y. Mao et al., 2005; Y. Mao et al., 2002;
J. Wu et al., 2000). In addition to TK1’s potential as a histological biomarker, TK1 is useful as a diagnostic
and prognostic serological biomarker. In recent years, TK1 has also been used as an imaging tool in positron
emission tomography (PET). The diversity of TK1’s clinical applications and its apparent advantage over other
proliferation markers warrants a closer look into its biology and clinical relevance. In fact, experts have
estimated that “in the next 5-10 years [2013-2018] it may be presumed that thymidine kinase will become a
part of the recommended procedures for follow-up in most haematological malignancies and in solid tumors”
(Ondrej Topolcan & Holubec, 2008). As a result, this review seeks to highlight these recent advances which
have propelled TK1 forward into clinical view.

2 Biology of TK1
2.1 TK1 and TK2 Isoforms
There are two isoenzymes of thymidine kinase: TK1 and TK2. Initially TK1 was identified as TK-fetal while
TK2 was identified as TK-adult due to their prevalence in fetal or adult tissue, respectively (Madec et al.,
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1988; Munch-Petersen, 1990). TK1 (TK-fetal) was overexpressed in fetal tissue as well as several types of
tumors, including breast, colon, lung, and a variety of haematological malignancies (Catalano et al., 1989; De
Blasio et al., 1990; Madec et al., 1988; Munch-Petersen, 1990; Musto et al., 1989; Weber et al., 1990). TK2
(TK-adult) was found at stable levels in adult tissues and did not fluctuate with the cell cycle (Q. He et al.,
1991). This is primarily because TK2 is directed to the mitochondria by a 40 amino acid leader sequence, and
is responsible for maintaining dTTP pools in the mitochondria, independent of the cell cycle (Saada et al.,
2001; L. Wang & Eriksson, 2000). Apart from their basic function of maintaining dTTP pools, TK1 and TK2
vary considerably in their basic biology and their relationship to disease. Since TK2 does not play a prominent
role in malignancy and is thoroughly reviewed elsewhere, the remainder of this review will focus on TK1
(Munch-Petersen, 2010; Priego et al., 2012).
2.2 TK1 Function
During DNA synthesis, nucleotides are either synthesized de novo or through the salvage pathway where they
are recycled from intracellular and extracellular sources. TK1 is one of two major salvage pathway kinases
responsible for maintaining the cellular nucleotide pool (Reichard, 1988). TK1 is primarily responsible for the
phosphorylation of deoxythymidine (dT). Its product, dTMP, is then subsequently phosphorylated and
incorporated into the DNA as dTTP (Reichard, 1988). Expectedly, dTTP helps to regulate this process as it
inhibits TK1, the rate-limiting step of this process (Q. He et al., 2002; Munch-Petersen, 2009). Deoxycytidine
kinase (dCK) is another salvage pathway kinase which primarily phosphorylates deoxycytidine in addition to
deoxyadenosine and deoxyguanosine (Bohman & Eriksson, 1988; Reichard, 1988; Sarup & Fridland, 1987). In
2012, Austin et al. demonstrated that TK1 can help counteract dCK inactivation and restore dCTP levels,
illustrating the complex and possibly redundant role of TK1 in maintaining the nucleotide pool balance (Austin
et al., 2012). Although ATP and dT are the primary substrates of TK1, several thymidine analogs such as 3’azido-2’,3’dideoxythymidine (AZT), 3’-fluoro-2’,3’dideoxythymidine (FLT) have also been utilized as TK1
substrates in clinical applications. One major advantage of AZT and FLT is the lack of confounding
phosphorylation by TK2. Munch-Petersen et al. demonstrated that TK2 does not phosphorylate FLT and has a
very poor capacity to phosphorylate AZT compared to its typical dT substrate (Eriksson et al., 1991; MunchPetersen et al., 1991). The clinical applications of these substrates will be discussed in more depth in 3.1 TK1
Methods of Detection and 3.7 TK1 Imaging-Positron Emission Tomography (PET).
Under normal proliferating conditions, TK1 is regulated by the cell cycle (Kauffman & Kelly, 1991).
TK1 levels are very low or barely detectable during G1 phase and begin to increase during late G1 phase (N.
Wang et al., 2001). TK1 levels peak during S phase at concentrations near 200 nM, at least 10-fold higher than
levels during G1 phase (Kauffman & Kelly, 1991; Munch-Petersen et al., 1993; Mutahir et al., 2013; Sherley &
Kelly, 1988). Interestingly, Sherley et al. reported that under normal conditions, TK1 mRNA only increased 3fold or less, compared to the 15-fold increase in protein levels, during the cell cycle (Sherley & Kelly, 1988).
They also determined that the rate of [35S] incorporation during S phase was 12-fold more efficient than during
the G1 phase (Sherley & Kelly, 1988). Indicating that the rapid increase in TK1 levels during S phase was a
result of an increase in the efficiency of TK1 translation, rather than an increase in transcription. This finding
is particularly interesting in light of a study by Chou et al. in which a 5’-untranslated region (5’UTR) allowed
translation of TK1 mRNA to be cap-independent (Chou & Chang, 2001). Munch-Peterson et al. has since
demonstrated that this rapid increase in TK1 is also a result of conversion from an inactive dimeric to the
active tetrameric TK1 form (Munch-Petersen, 2010). On the other hand, Kauffman et al. reported that the rapid
decrease in TK1 levels during the G2 phase is primarily a result c-terminal dependent degradation (Kauffman
& Kelly, 1991).
Closely associated with TK1’s role in maintaining nucleotide pool balance throughout the cell cycle,
is its role in DNA repair. Several studies confirm that TK1 levels increase as a result of DNA damage,
especially following irradiation or chemotherapy (Y. L. Chen et al., 2010; Haveman et al., 2006; Kreder et al.,
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2002). In 2010, Chen et al. further characterized the connection between TK1 and DNA damage by showing
p53-/- tumor cells increased TK1 levels in response to DNA damage while p53 wildtype tumor cells did not (Y.
L. Chen et al., 2010). This connection between TK1 and p53 has been corroborated in other studies which
report normal p53 function is required to maintain cell cycle dependent regulation of TK1, and upon p53 loss,
there is a compensatory increase in TK1 (Radivoyevitch et al., 2012; Schwartz et al., 2004). Closer analysis of
this connection revealed that the increase in TK1 levels following DNA damage is dependent on p21 (Y. L.
Chen et al., 2010). In fact, Huang et al. showed that the c-terminal domain of p21 interacts with TK1 and
overexpression of TK1 prevents p21-dependent growth suppression (D. Y. Huang & Chang, 2001). These
results challenged the traditional role of TK1 in tumor cells. For example, Chen et al. determined that TK1
knockdown did not affect the growth of tumor cells, even though the levels of dTTP significantly decreased
(p<0.01) (Y. L. Chen et al., 2010). Their results support the conclusion that the primary role of TK1 in tumor
cells is DNA repair rather than to provide sufficient dTTP levels for replication and growth. This conclusion is
supported by several other studies which have shown that functional TK1, resulting in increased dTTP levels,
is essential for DNA repair in tumor cells following treatment with an alkylating agent or radiation (al-Nabulsi
et al., 1994; Jeong et al., 2004; McKenna et al., 1985; Wakazono et al., 1996). In this way, TK1 operates as a
mechanism of resistance which promotes tumor cell survival.
Another surprising and obscure function of TK1 is its possible connection to the immune system. In
an effort to understand the biological significance of TK1, Dobrovolsky et al. created TK1 knockout (TK -/-)
mice (Dobrovolsky et al., 2003). These mice exhibited kidney abnormalities including sclerosis of kidney
glomeruli, serous secretion by the salivary gland instead of mucous secretion, a significant decrease in splenic
lymphocytes, abnormal lymphoid structure of the spleen, and occasional inflammation of the arteries
(Dobrovolsky et al., 2003). Given TK1’s connection to proliferation, the cells most likely to be affected in
TK1 knockout mice would be rapidly dividing cells or fetal cells. Interestingly, this was not the case, as the
most pronounced changes were found in the kidney and salivary glands (Dobrovolsky et al., 2003). The kidney
abnormalities coincide with a report by Zaharevitz et al. indicating that mouse kidney cells preferentially rely
on the nucleotide salvage pathway over de novo synthesis (Zaharevitz et al., 1992). Similarly, Luo et al.
reported that TK1 activity was 3-fold higher in normal human kidney cells compared to renal cell carcinoma
(Luo et al., 2009; Luo et al., 2010). To date, this is the only human tissue in which TK1 is overexpressed in
normal tissue compared to malignant tissue. Unfortunately, the mechanisms behind the TK1 knockout mice’s
kidney and salivary gland abnormalities are not understood, nor are the kidney’s preferential use of the salvage
pathway. On the other hand, the remaining phenotypic changes of the TK1 knockout mice indicate an
attenuated or dysfunctional immune system (Dobrovolsky et al., 2003). In particular, the cause of the
significant decrease in splenic lymphocytes is not known but could be a result of either failure to activate or
improper maturation (Dobrovolsky et al., 2003). There is recent evidence that TK1 is overexpressed during
hematopoiesis in normal human bone marrow indicating a potential role of TK1 in the maturation of
lymphocytes (Alegre et al., 2013). TK1 may also play a role in autoimmunological diseases, especially of the
thyroid (Karbownik et al., 2003; Schwartz et al., 2004). In 2003, Karbownik et al. reported TK1 expression
was 2-fold higher in leukocytes from patients with Hashimoto’s and Graves’ disease compared to healthy
controls (Karbownik et al., 2003). Although the connection between TK1 and the immune system is largely
unexplored, it seems clear that it plays a significant role in maintaining normal immune function.
Overall, the biochemical role of TK1 is clear. In normal cells, TK1 is responsible for maintaining the
dTTP nucleotide pool in a cell cycle-dependent manner. Additionally, TK1 plays an invaluable role in DNA
repair and survival of tumor cells following DNA damage. The biological significance of TK1 is less
understood and somewhat puzzling. Normal TK1 function is essential for proper development and function of
the kidney and salivary gland although these mechanisms are not understood (Dobrovolsky et al., 2003). TK1
also appears to be necessary for the normal function of the immune system and may play a role in its
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deregulation. Another unexplored and puzzling function of TK1 is its role in the circulatory system of cancer
patients. TK1 is well-known for its elevation in the serum of cancer patients, which will be discussed in detail
later. However, the mechanism by which TK1 enters the serum and its function in the serum has been largely
unexplored. Perhaps, its function in the serum is connected to regulating the immune system. Further analyses
are needed to understand this connection and its significance.
2.3 TK1 Structure
Human TK1 (hTK1) as a monomer, in its most basic structure, is 234 amino acids in length with a molecular
weight of 25.5 kDa (Bradshaw & Deininger, 1984). TK1 adopts a variety of oligomeric forms although it is
most commonly found as a dimer or tetramer, approximately 53 kDa and 100 kDa respectively (MunchPetersen, 2009). In 1993, Munch-Petersen reported that the TK1 dimer was the low-efficiency form of the
enzyme with a high Km (15uM). On the other hand, the TK1 tetramer was a high-efficiency form with a low
Km (0.7uM) and was reported to have 30-fold increased efficiency compared to the dimer in catalyzing its
phosphoryl transfer reaction (Munch-Petersen, 2009).
The crystallization of TK1 indicates that the tetrameric form is composed of a dimer of dimers
(Segura-Pena, Lutz, et al., 2007). As such, there are two distinct monomer-monomer interfaces labeled strong
and weak. The weak interface is primarily stabilized indirectly by ATP, the donor molecule, while the strong
interface is stabilized directly through many polar interactions (Segura-Pena, Lutz, et al., 2007). Each
monomeric subunit consists of an α/β-domain which is most similar to DNA binding proteins including RecA
(Welin et al., 2004). As TK1 catalyzes the conversion of dT to dTMP, the overall structure remains unaltered
although Welin et al. reported two regions which do change conformation, the P loop and Lasso loop (SeguraPena, Lichter, et al., 2007; Welin et al., 2004). These conformational changes occur independently and are only
dependent on their respective substrates (Segura-Pena, Lichter, et al., 2007). The P loop or flexible loop
consists of residues Gly26-Ser33 in hTK1 and is where the phosphate donor, typically ATP, is held (Birringer
et al., 2005; Welin et al., 2004). When ATP binds, this P loop becomes rigid and forms an ordered β-hairpin
structure (Segura-Pena, Lichter, et al., 2007). An essential element of the P loop and ATP binding is
stabilization by a magnesium ion (Segura-Pena, Lutz, et al., 2007). This magnesium ion is surrounded by two
phosphate groups of ATP, three water molecules, and a threonine residue (Segura-Pena, Lutz, et al., 2007;
Welin et al., 2004).
On the other hand, the lasso loop consists of residues Leu166-Lys180 and is where the phosphate
acceptor molecule, typically dT, is found (Welin et al., 2004). Similar to the P loop, the binding of dT to the
lasso loop is closely associated with a metal ion, zinc (Birringer et al., 2005). This zinc-binding motif is
located between residues Thr150-Lys191, and is held in place by four cysteines at residues 153, 156, 185, and
188 (Birringer et al., 2005). This situates zinc within 20 Å of the active site, highlighting its crucial role in
TK1’s phosphoryl transfer reaction (Welin et al., 2004). The pivotal role of zinc is confirmed by Ishikawa et
al. who reported that TK1 expression in rats fed a low-zinc diet was reduced by 50% and the percentage of
cells in S phase was significantly reduced compared to controls (Ishikawa et al., 2008). The actual
phosphorylation reaction of TK1 requires coordination from several different residues. The lasso loop
stabilizes dT in a hydrophobic pocket by Met28, Phe101, and Leu24, while the C5 of dT makes contact with
Thr163 (Birringer et al., 2005). Glu98 acts as a base which accepts a proton from the 5’OH of dT while Lys32
of the P loop transfers a phosphate group to this 5’OH of dT (Birringer et al., 2005; Segura-Pena, Lutz, et al.,
2007). The transitional state during the conversion of dT to dTMP is stabilized by Arg60 (Welin et al., 2004).
The remarkable and unique component of TK1’s reaction is that the backbone of the protein is involved in this
reaction, rather than the side chains (Birringer et al., 2005). This enables hTK1 to limit its substrates to ensure
greater specificity unlike the herpes simplex virus TK which has a broad range of substrates and primarily uses
side chains to catalyze its reaction (Birringer et al., 2005).
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In addition to inducing a conformational change at the monomeric level, ATP binding induces
reversible TK1 tetramerization (Munch-Petersen et al., 1993). In the presence of ATP, TK1 switches from a
dimer to a tetramer (Kuroiwa et al., 2000; Munch-Petersen et al., 1993). In 2009, Munch-Petersen determined
that this TK1 regulatory switch between the dimer and tetramer could occur with ATP, UTP, GTP or CTP
indicating that the sugar and base were not involved in tetramerization, rather only the phosphate group was
essential (Munch-Petersen, 2009). Although any of these nucleotides were sufficient to induce tetramerization,
only ATP could act as a phosphate donor, indicating that ATP-dependent tetramerization and phosphorylation
of dT are independent events (Munch-Petersen, 2009). In 2006, Zhu et al. reported that deletion of the cterminal of TK1 did not effect this ATP-dependent tetramerization (Zhu et al., 2006). On the other hand, Li et
al. determined that serine-13 phosphorylation of TK1 disrupted ATP-induced tetramerization, (C. L. Li et al.,
2004). Additionally, Mutahir et al. demonstrated how the weak dimer interface is involved in this ATPdependent regulatory switch. For example, they reported that this interface was composed of two antiparallel
α1 helices in which there was only 7.5 Å separating the two dimers at the residues Phe29 and Ile45 (Mutahir
et al., 2013). A study by Segura-Pena et al. supported this conclusion in that two additional cysteine residues
within the α1 helix, at the weak dimer interface, locked TK1 in the tetramer form (Segura-Pena, Lichter, et al.,
2007). In addition to causing tertiary structural changes, the binding of ATP can also induce the transformation
of a closed, inactive tetramer to an open, catalytically active tetramer (Segura-Pena, Lichter, et al., 2007).
Sengura-Pena et al. reported that during this transformation, the weak dimer interface expands by almost 10%
and rotates by 11 degrees (Segura-Pena, Lichter, et al., 2007).
Interestingly, ATP is not the only mechanism by which this regulatory switch can be activated. In
2009, Munch-Petersen reported that the concentration of TK1 can also induce a dimer to tetramer switch, at
concentrations higher than 0.2 mg/ml, regardless of ATP (Munch-Petersen, 2009). This confirms results by
Birringer et al. who demonstrated that recombinant TK1 was exclusively found in the tetramer at
concentrations ranging from 0.4-20 mg/ml (Birringer et al., 2006). Munch-Petersen surprisingly showed TK1
remains as a tetramer at low concentrations (6µg/ml) when analyzed immediately but when the same sample
was stored diluted for more than 2 weeks before analysis, TK1 existed as a dimer (Munch-Petersen, 2009).
This illustrated that the dimer to tetramer switch is a very slow process which can help explain some
discrepancies among other studies.
The dimer to tetramer switch of TK1 does not exist in all organisms and its study among various
organisms hints at the structural evolution of TK1 (Mutahir et al., 2013). In a study of the oligomeric structure
of TK1 among ten organisms, Mutahir et al. determined that TK1 was only found as a dimer in bacteria, plant,
and Dictyostelium while all vertebrates and C. elegans had tetrameric TK1. Therefore, they deduced that the
origin of the TK1 tetramer occurred after the split between the animal and Dictyostelium lineages (Mutahir et
al., 2013). Furthermore, the regulatory switch from the TK1 dimer to tetramer did not exist in C. elegans and
Danio rerio (zebrafish) and was only fully functional in birds and mammals (Mutahir et al., 2013). This
indicated that although the TK1 tetramer was present in all vertebrates, the TK1 regulatory switch from the
dimer to tetramer originated with the warm-blooded vertebrate lineage (Mutahir et al., 2013). Further work,
including the testing of TK1 from more organisms, is still needed to understand the intricate mechanisms
associated with the evolution of TK1’s activities.
One intriguing and challenging hurdle in TK1’s journey from bench-to-bedside has been its unique
structure in malignancy. Initially, Karlstrom et al. reported that the majority of serum TK1 from leukemia
patients had a molecular weight of approximately 730 kDa with only a small percentage at 58 kDa (Karlstrom,
1990). On the other hand, only the 58 kDa form could be found in proliferating HeLa cells (Karlstrom, 1990).
Since then, Sharif et al. reported this high molecular weight form could be found in CEM cells, although the
majority of TK1 was found in the 40-100 kDa fraction (Sharif, Kiran Kumar, et al., 2012). They also
confirmed earlier reports as they found that 90% of the TK1 in human leukemia serum was in this same high
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molecular weight form, 300-720 kDa (Sharif, Kiran Kumar, et al., 2012). This high molecular weight form has
made the detection of TK1 protein levels problematic for two major reasons. First, TK1 activity and protein
levels do not correlate unless reducing agents are used, which also partially reduce immunoglobulins (Q. M.
He et al., 2005; Sharif, Kiran Kumar, et al., 2012). Additionally, recombinant TK1 does not reflect the same
quaternary structure as serum TK1, making it difficult to use an appropriate TK1 positive control for
immunoassays. Sharif et al. suggested that methionine and tyrosine residues of TK1, in addition to 7 of TK1’s
11 cysteine residues, may contribute to the high molecular weight form of serum TK1. This conclusion was
supported as they demonstrated that human serum TK1was found in oligomeric structures irrespective of
reducing agents (Sharif, Kiran Kumar, et al., 2012). It is also unclear as to whether this TK1 high molecular
weight aggregate is a homo- or hetero-oligomer, indicating the possible existence of a protein binding partner.
Overall it can be seen that the structure of TK1 influences not only its function, but also its regulation
and detection. A thorough understanding of the secondary structures and residues involved in TK1’s
phosphoryl transfer reaction enable us to design clinically relevant substrates such as AZT and FLT. TK1’s
structure can also help us design TK1 inhibitors which may re-sensitize otherwise resistant tumors.
Additionally, a sound understanding of the structure of TK1 in malignancy will ultimately lead us to develop
better methods of detection which could be used in the clinic. Finally, the structure of TK1 is particularly
informative and essential in understanding the regulation of TK1 since post-translational modifications play a
major role in its mechanism of control.
2.4 TK1 Mechanisms of control
TK1 is tightly regulated by the cell cycle. TK1 is found at very low levels in G1 phase, peaks during S phase,
and is degraded during late G2/M phase (Kauffman & Kelly, 1991; Sherley & Kelly, 1988; N. Wang et al.,
2001). Phosphorylation is one common cell cycle mechanism which targets proteins for Skp, Cullin, F-box
containing complex (SCF)-mediated degradation (Harper, 2002). Initially, Chang et al. reported that TK1 was
heavily phosphorylated in rapidly dividing cells and partially hypo-phosphorylated in M phase-arrested cells,
which suggested phosphorylation may play a role in TK1 regulation (Chang et al., 1994; Q. M. He et al., 1996;
Lin et al., 2003). Additionally, Ke et al. demonstrated that phosphorylation of serine-13 targets TK1 for SCFmediated degradation in yeast (Ke et al., 2003). However, Ke et al. later determined that the APC/C-Cdh1
pathway is responsible for TK1 degradation in mammalian cells, not the SCF complex (Ke & Chang, 2004).
This indicates that the cell cycle-dependent phosphorylation does not play a role in TK1 degradation (Ke &
Chang, 2004). This APC/C-mediated degradation of TK1 explains the very low levels of TK1 at the beginning
of the cell cycle, but it does not explain the rapid increase proceeding S phase. Munch-Petersen et al. has
demonstrated that this rapid increase is mediated in part by the TK1 regulatory switch from an inactive dimer
to an active tetramer (Munch-Petersen, 2009; Munch-Petersen et al., 1995; Munch-Petersen et al., 1993).
During G0 and G1 phases, TK1 exists as a dimer with estimated concentrations at 0.03-0.09 µg/ml, much lower
than the concentration which induces a dimer to tetramer switch (Munch-Petersen et al., 1995; Munch-Petersen
et al., 1993). On the other hand, TK1 exists as a tetramer during S phase with estimated concentrations at 4-6
µg/ml (160-240 nM) (Munch-Petersen et al., 1995; Munch-Petersen et al., 1993). This transition is likely
regulated by TK1 concentration during G1 phase (since the concentration is so low), and ATP-dependent
tetramerization is responsible for the increased TK1 activity during S phase (Munch-Petersen et al., 1995).
Interestingly, phosphorylation in rapidly dividing cells appears to play a role in this dimer to tetramer
transition as well, rather than as a target for degradation (C. L. Li et al., 2004). Li et al. demonstrated that
serine-13 phosphorylation disrupts ATP-dependent tetramerization, and as a result, TK1 is preferentially found
as an inactive dimer (C. L. Li et al., 2004). Since cdc2 kinase phosphorylates serine-13 of TK1 during G2/M
phase, phosphorylation helps to regulate the tetramer to dimer switch and thus decrease TK1 activity following
S phase (Chang et al., 1998; Chang et al., 1994).
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Protein degradation plays an important role in maintaining appropriate levels of TK1 throughout the
cell cycle, as briefly discussed previously. Closely associated with protein degradation is the half-life of TK1.
Zhu et al. reported that a 44 amino acid deletion of TK1’s c-terminus increased its half-life to 500 minutes,
compared to 83 minutes for wild-type TK1 (Zhu et al., 2006). This increased stability illustrated the crucial
role of the c-terminus in TK1degradation. Similarly, Demeter et al. reported the half-life of TK1 from normal
ovarian epithelial cells was 82 minutes compared to 36 minutes for that of malignant ovarian cells (Demeter et
al., 2001). Posch et al. showed that the unstable, decreased half-life (<60 minutes) of TK1 can also be a result
of mutation of the binding sites for ATP or dT (Posch et al., 2000). Although this may explain the decreased
half-life in malignancy, these mutant TK1s did not increase with proliferation (Posch et al., 2000). Further
work is needed to understand the mechanism by which TK1 activity is increased in malignancy since it appears
to be unstable in cancer cells compared to that in wildtype cells.
Under normal conditions, TK1 is polyubiquitinylated during the G2/M phase which targets it for
degradation by the APC/C pathway (Ke & Chang, 2004). Additionally, Ke et al. demonstrated that Cdh1
mutant inhibited TK1 degradation whereas a Cdc20 mutant had no significant effect on TK1 degradation,
indicating that TK1 is degraded by the APC/C-Cdh1 complex (Ke & Chang, 2004). Cdh1 is the rate-limiting
step for this degradation, as it binds to the KEN box (residues 203-205 of the c-terminal end of TK1) (Ke &
Chang, 2004). This degradation process does not occur when dT is bound to TK1 (Ke et al., 2007). In addition
to acting as a control mechanism for degradation, dT-bound TK1 also reverses Cdh1-mediated expression of
TK1(Ke et al., 2007).
In addition to post-translational modifications such as ubiquitination or phosphorylation, TK1 is also
subject to transcriptional regulation. The promoter region of TK1is suppressed by a G-quadruplex motif
located between -13 and +8 relative to the transcription start site (Basundra et al., 2010). Although this region
controls TK1 expression generally, TK1’s promoter also has regions responsible for cell cycle-dependent TK1
expression. For instance, initially the promoter region of TK1 (-441 to -63 relative to the transcriptional start
site) was identified as the region responsible for cell cycle regulation (Y. K. Kim et al., 1988). Subsequent
analysis by Kim et al. determined that the minimum fragment which conferred cell cycle regulation was a 70
bp region between -133 and -64 which was named the cell cycle regulatory unit (CCRU) (Y. K. Kim & Lee,
1991). Within this region, an inverted CCAAT sequence and one G-C rich motif were found between -84 and 64 (Y. K. Kim & Lee, 1992). Kim et al. determined that without this 20 bp region, -84 to -64, the level of
transcription dropped to barely detectable levels, indicating that this region acts as an enhancer element (Y. K.
Kim & Lee, 1992). Therefore, even though the actual cell cycle control element is found between -133 and 84, the enhancer element from -84 to -64 is also required for proper expression (Y. K. Kim & Lee, 1992). Yi
binding factor is known to regulate cell cycle-dependent TK1 expression in mice by binding to the Yi
consensus sequence during late G1/S phase (Dou et al., 1991). Similarly, a Yi-related sequence was identified
in the human TK1 promoter between -109 and -84, which is important for cell cycle-dependent TK1
expression (Y. K. Kim & Lee, 1992). Li et al. also determined that cyclin A and p33cdk2 complexes were
constitutively associated with this site, -109 to -84 (E. C. Kim et al., 1996; L. J. Li et al., 1993). Additionally
the binding activity of the cyclin A/p107 complex was increased throughout the S phase and correlated to an
increase in TK1 mRNA levels (L. J. Li et al., 1993). Another protein which is associated with cell cycledependent TK1 expression is CCAAT binding protein for TK gene (CBP/tk) (Pang & Chen, 1993). This
protein binds to the CCAAT sequence located from -91 to -64 of the TK1 promoter, which is known to
contribute to promoter strength (Good et al., 1995; Lipson et al., 1995; X. Mao et al., 1995; Pang & Chen,
1993). NF-Y binding to the TK1 promoter is responsible for recruiting CBP/tk to the CCAAT sequence and
Sp1 to the region -118 to -113 (Chang et al., 1999; Chang & Liu, 1994). The transcription and posttranslational control of TK1 play an important role in maintaining normal TK1 function in a cell. It is through
the deregulation of this process, that we begin to see its unregulated elevation in malignancy.
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3 TK1 in Malignancy
TK1 has diagnostic, prognostic and therapeutic potential in malignancy. This is true for both TK1 found in the
serum (sTK1) as well as TK1 expressed in tumor tissue. An understanding of TK1’s various methods of
detection is critical to understanding sTK1 diagnostic and prognostic potential.
3.1 TK1 Methods of Detection
The unique structure of sTK1, found in its high molecular weight form (300-720 kDa), has been a major
challenge in developing a clinically relevant methods of detection. Furthermore, He et al. reported a puzzling
observation in which malignant serum, high in TK1, diluted with normal serum reduced both TK1
concentration and activity more than expected (Q. M. He et al., 2005). They also reported this same finding
when malignant serum was diluted with BSA, indicating there is a factor in normal human and calf serum that
destabilizes TK1 (Q. M. He et al., 2005). Another puzzling and unique aspect of sTK1 is its long half-life. The
half-life of TK1 is one hour in mouse EAT cells, four hours in HeLa cells, and a surprising 30 days in serum
(Q. He et al., 1991; Q. He et al., 2000; Hengstschlager et al., 1994). The 30 day half-life of sTK1 has been
confirmed for both breast cancer and gastric cancer (Q. He et al., 2000; Zou et al., 2002). Clearly, the
environment of sTK1 contributes to its unique structure and properties in ways that can’t always be predicted
by studying TK1 in cancer cells alone.
Consequently, the traditional method of quantifying TK1 is by measuring its activity using a
radioassay. For this assay, [3H]-dThd is phosphorylated using either ATP or CTP (K. L. O'Neill et al., 1986).
[3H]-dTMP then absorbs to ion exchange DE81 filter paper, is washed and radioactivity is measured. TK1 only
utilizes ATP while TK2 utilizes both ATP and CTP, so the relative contribution of TK1 can be determined by
using both ATP and CTP separately (Bristow et al., 1988). In addition to these substrates, the reaction mixture
varies slightly in its additives such as MgCl2 and/or KCl, but a reducing agent, to break disulfide bonds, is
crucial for the assay to ensure reliable, consistent results (K. L. O'Neill et al., 1986; Sharif, von Euler, et al.,
2012a). In 2012, Sharif et al. optimized this traditional radioassay specifically for human sTK1 (Sharif, von
Euler, et al., 2012a). They reported the area under the curve (AUC) was 0.94 with a sensitivity and specificity
of 0.89 and 0.74 respectively (Sharif, von Euler, et al., 2012a). The traditional TK radioassay was
commercialized and sold as a kit. Instead of [3H]-dThd, the kit utilizes [125I]-deoxyuridine (H. P. Von Euler et
al., 2009). This same technology, slightly modified, is sold as either the radio-receptor analysis (RRA) kit
(Immunotech, Czech Republic) or more commonly as the TK Prolifen assay or TK-REA (DiaSorin AB,
Sweden) (Span et al., 2000; H. P. Von Euler et al., 2009; Votava et al., 2007). Unfortunately, Svobodova et al.
reported that sTK1 activity levels, using the RRA test, were significantly elevated in relatively few cases of
1087 cancer patients compared to healthy controls (Svobodova et al., 2007). Despite the low cost of this test
($4/sample), these results should be interpreted with caution since they do not always reflect typical trends of
TK1 in malignancy (Votava et al., 2007). Today, the TK-REA kit is commonly used as a method of
comparison for new ways to quantify TK1. For example, the TK-REA has been used in side-by-side
comparisons with new assays especially the Liason, described later (Ohrvik et al., 2004). On the other hand,
the traditional, non-commercialized radioassay has been the standard method to determine TK1 activity since
the late 1980’s, and has also been used in several side-by-side comparisons (Luo et al., 2009; McKenna et al.,
1988; K. O'Neill et al., 1987; K. L. O'Neill et al., 2001; K. L. O'Neill, Hoper, et al., 1992; K. L. O'Neill,
McKelvey, et al., 1992; Robertson et al., 1990; Thomas et al., 1995). Unfortunately, there are several
disadvantages of the traditional radioassay and TK-REA. For example, these tests are radioisotope-based,
relatively expensive, time consuming, require specialized training and facilities, are relatively inconsistent, and
have relatively low sensitivity (F. Zhang et al., 2001).
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Fortunately, in the late 1990’s and early 2000’s, anti-TK1 antibodies prompted the development of
immunoassays which could be clinically applicable. TK1-specific antibodies proved problematic since TK1 is
highly conserved among mammals (89-97% among humans, mice, and rabbits). Therefore, currently the only
clinically robust antibodies are ones which bind the c-terminal fragment or the 24-amino acid active site called
the lasso loop of TK1 (H. von Euler & Eriksson, 2011). In 2001, Zhang et al. reported a TK1-specific
monoclonal antibody which blocks the active site of TK1. This was later used to develop an enzyme-linked
immunosorbent assay (ELISA) (F. Zhang et al., 2001). This ELISA showed a strong correlation with the
traditional radioassay and gave similar results without many of the disadvantages associated with the
radioassay. The majority of clinical biomarkers today utilize a similar technique called a Sandwich ELISA.
The Sandwich ELISA is highly specific and sensitive since it relies on two TK1-specific antibodies. In 2009,
Carlsson et al. developed a Sandwich ELISA with AUC values of 0.56, 0.73, and 0.64 for postoperative,
disease recurrence, and chemotherapy treated patients respectively (Carlsson et al., 2009). AUC values for
useful biomarkers are typically closer to 0.86 as is the case with CA 72-4, a biomarker for gastric cancer
(Fernandez-Fernandez et al., 1996). Unfortunately, this TK1 Sandwich ELISA has AUC values near 0.5, the
value indicating the assay has no predictive power. Furthermore, the sensitivity and specificity of this assay
were surprisingly low, indicating that it is not a clinically useful TK1 immunoassay (Carlsson et al., 2009). As
a result, no further studies have been conducted with this assay. There is still a need for a robust Sandwich
ELISA which can be quickly integrated into the clinic to aid in diagnosis and prognosis of malignancy.
In order to circumvent the highly conserved nature of TK1 and make robust, high-affinity TK1
antibodies, Wu et al. developed a chicken polyclonal IgY antibody specific to the c-terminus of hTK1 (C. Wu
et al., 2003). This IgY TK1 antibody was used to develop a dot blot to quantify TK1 protein levels (TK1p)
instead of TK1 activity (TK1a) (C. Wu et al., 2003). This dot blot is highly sensitivity with the lowest
detectable concentration of TK1p at 33.3 pg/ml (C. Wu et al., 2003). In the past 10 years, this dot blot has been
used in 14 studies including over 3,500 cancer patients and almost 70,000 healthy individuals (Y. Chen et al.,
2010; Chen et al., 2011; Chen et al., 2008; E. He et al., 2010; Q. M. He et al., 2005; Kameyama et al., 2011; H.
X. Li et al., 2005; Z. Li et al., 2010; Liu et al., 2011; Pan et al., 2010; C. Wu et al., 2003; X. H. Xu et al., 2008;
J. Zhang et al., 2006). In 2011, Chen et al reported the AUC of the dot blot for a healthy screen of 35,365
individuals was 0.96 (Chen et al., 2011). They also reported that the specificity and sensitivity were 0.99 and
0.78 respectively, while only 0.8% of healthy city-dwellers had elevated sTK1 levels, which typically
corresponded to pre-malignant conditions (Chen et al., 2011). As of 2010, this dot blot has been
commercialized, and the kit was approved by the Supervision Authority for Food and Medicine in China (Pan
et al., 2010). This commercialized, approved kit has been one of the biggest factors in propelling TK1 into
clinical view during the past few years.
There have been several reports, including use of this commercial dot blot, which have demonstrated
that TK1a and TK1p do not correlate (Kristensen et al., 1994; Luo et al., 2009; Sharif, Kiran Kumar, et al.,
2012). This has provided the rationale for some to focus on TK1a rather than TK1p. A focus on TK1a also
circumvents the challenges associated with developing TK1 antibodies for immunoassays. As a result, Von
Euler et al. developed a commercialized competitive ELISA to quantify TK1a using AZTMP antibodies (H. P.
Von Euler et al., 2009). This novel assay, currently referred to as the Liaison TK assay, simultaneously
exploits the advantages of sensitivity and accuracy associated with an ELISA and negates the controversy
regarding protein levels and activity. Although this assay is advantageous in that TK2 does not phosphorylate
AZT, yielding no confounding TK2 activity, the Liaison TK assay has some disadvantages (Munch-Petersen et
al., 1991). For example, hTK1 is known to phosphorylate dT three times more efficiently than AZT (Eriksson
et al., 2002). Similarly, Sharif et al. reported that canine TK1 phosphorylated AZT three times more efficiently
than hTK1 (Sharif, Kiran Kumar, et al., 2012). This indicates that the Liason TK assay may be better suited for
screening canine malignancies than human malignancies. In fact, many of the studies involving the Liaison TK
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assay have investigated canine malignancies (Sharif, von Euler, et al., 2012a; Thamm et al., 2012; H. P. Von
Euler et al., 2009). Additionally, Ohrvik et al. demonstrated that the AZTMP antibodies can cross-react with
endogenous antibodies in human serum (Ohrvik et al., 2004). In comparison with other TK assays, the Liaison
TK assay showed significant linear correlation with the TK REA (p<0.0001) (Sharif, von Euler, et al., 2012a;
H. P. von Euler et al., 2006; H. P. Von Euler et al., 2009).
The Liaison TK assay, traditional TK assay, TK REA, and TK1 dot blot are among the most popular
and well-established methods of detection for TK1. There have been a few other assays which have been
developed either for commercial use or research purposes. The DiviTum kit (Biovica/Ronnerbol, Sweden) is
another ELISA which measures TK activity, except it uses bromo-deoxyuridine as a substrate (Nisman et al.,
2013). DiviTum and Liaison TK assays are very similar although the DiviTum is a manual assay and the
Liaison is automated. Nisman et al. demonstrated that both assays were correlated and had efficacy in
predicting recurrence preoperatively in breast cancer patients (Nisman et al., 2013). Similarly, the DiviTum
assay is efficacious in renal cell carcinoma and non-small cell lung cancer in addition to breast cancer
(Korkmaz et al., 2013; Nisman, Yutkin, et al., 2010). Faria et al. measured TK activity in hepatocellular
carcinoma patients using liquid chromatography-MS/MS through the phosphorylation of FLT (Faria et al.,
2012). Alternatively, Tzeng et al. utilized capillary electrophoresis to separate and quantify dTMP following
the traditional TK assay, negating the need for radioisotopes (Tzeng & Hung, 2005). On the other hand, some
have developed methods to estimate protein concentrations while still circumventing the challenge of TK1
antibodies. Stalhandske et al. reported a PCR-based real-time assay in which they simultaneously measured
both TK1 and dCK levels (Stalhandske et al., 2013). These methods, although practical and valid, have not yet
gained widespread popularity. Nevertheless, a thorough understanding of the various methods of TK1
detection, including their limits and strengths, will help shed light on potential discrepancies found as we
explore the trends of TK1 in malignancy.
3.2

Serum-TK1 Diagnostic potential

Elevated sTK1in malignancy is a very early event. In 2008, Xu et al. reported 70% of pre-malignant cervical
cancer cases were accompanied by elevated sTK1 protein levels (X. H. Xu et al., 2008). Additionally, the
mean age of pre-malignant cervical cancer patients was 10 years earlier, compared to cervical cancer patients
(X. H. Xu et al., 2008). There have been 3 large Chinese health screens which sought to determine sTK1p
levels in healthy adults. In 2008, Chen et al. reported that in a health screen of 11,880 individuals, 0.5% had
elevated sTK1p levels, using a previously determined cut off value of 2 pM (Chen et al., 2008). Of the 0.5%
with elevated sTK1, 83% reported malignancy-related diseases including benign or hyperplasia tissues (Chen
et al., 2008). Similarly, a health screen involving 35,365 individuals revealed that 0.8% of urban-dwelling and
5.8% of oil-field workers had elevated sTK1p levels (Chen et al., 2011). Of the individuals with elevated
sTK1p, 8.8% developed new pre-malignancies or showed progression in existing pre-malignancies (Chen et
al., 2011). Additionally, elevated sTK1p levels were associated with a 3-5 fold increased risk of developing
malignancy within 5-72 months (Chen et al., 2011). This was confirmed in another health screen of 8,135
individuals in which 1.1% had elevated sTK1p levels (S. Huang et al., 2011). Huang et al. reported that of
those with elevated sTK1p, one individual developed liver carcinoma within 13 months and five individuals
showed malignancy-related disease progression within 19 months (S. Huang et al., 2011). Overall, incidence
of elevated sTK1p levels (>2pM) in healthy adults is low and is typically indicative of pre-malignant or
malignancy-related diseases. sTK1 levels appear to play a valuable role in early detection of malignancy which
may ultimately improve cancer mortality rates.
In addition to early detection, sTK1a and sTK1p levels are significantly elevated in a variety of
haematological and solid tumors. Initially, sTK1a was studied primarily in haematological malignancies.
Sharif et al. determined that sTK1 activity levels were significantly elevated in both chronic lymphocytic
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leukemia (CLL) and myelodysplastic syndrome (MDS), a type of preleukemia (Sharif, von Euler, et al., 2012b;
W. Xu et al., 2009). In this study MDS sTK1 levels were the highest among the heamatological malignancy
group (Sharif, von Euler, et al., 2012b). This coincides with an earlier study which reported that elevated
sTK1a levels were indicative of progression of MDS into acute myeloid leukemia (AML) (Musto et al., 1995).
Significantly elevated sTK1a levels compared to healthy controls were also found in pre-treated acute
lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, and follicular lymphoma (K. L. O'Neill et al., 2007;
Pan et al., 2010; Prochazka et al., 2012). Although sTK1a levels were not initially thought to be a good
indicator for solid tumors, we now know elevated sTK1 levels are significantly elevated compared to controls
in virtually all solid tumors. This is true for malignant melanoma, systemic breast, preoperable primary breast,
gastric, kidney, bladder, non-small cell lung (NSCLC), esophageal, cardiac, cervical, ovarian, colon, rectum,
liver, head and neck, thyroid, and brain cancers, among others (Y. Chen et al., 2010; Elfagieh et al., 2012;
Fujiwaki et al., 2001; Q. He et al., 2000; Q. M. He et al., 2005; Z. Li et al., 2010; Liu et al., 2011; Nisman,
Allweis, et al., 2010; Nisman, Yutkin, et al., 2010; Robertson et al., 1990; Thomas et al., 1995; B. J. Wu et al.,
2013; C. Wu et al., 2003; W. Xu et al., 2009; J. Zhang et al., 2006; Zou et al., 2002). Additionally, several
studies have investigated whether there is a significant difference between benign and malignant tissue. He et
al. reported in a study of 9 types of carcinoma tissue that sTK1 levels of pre-treated malignancy were
significantly higher than either benign or noncancerous individuals (Q. M. He et al., 2005). These findings,
which indicate there is a significant difference in sTK1 levels in benign and malignant tissue, have been
confirmed in several studies, although there is no significant difference in sTK1 levels between benign kidney
and renal cell carcinoma (Q. He et al., 2000; Nisman, Yutkin, et al., 2010; X. H. Xu et al., 2008). High sTK1
levels typically indicate a more advanced grade, stage, increased T-values, and increased tumor size (Y. L.
Chen et al., 2010; H. X. Li et al., 2005; Z. Li et al., 2010; Nisman, Allweis, et al., 2010). Although some
studies have reported that sTK1 is associated with stage but not grade in tumors such as renal cell carcinoma,
esophageal, cardiac, and bladder carcinoma (Z. Li et al., 2010; Nisman, Yutkin, et al., 2010; J. Zhang et al.,
2006). It is difficult to determine whether or not sTK1 levels in general correlate with grade in each of these
carcinoma types, since this information was not always studied. A more thorough analysis of each cancer type
is needed to determine if these results are specific to the cancer type or a result of the study’s sample
population. The overall trends of sTK1 levels and their early elevation among a wide variety of malignancies
are clear. Over the years, many cancer biomarkers have been validated and show clinical promise. However,
the unique ability of sTK1 to predict risk for malignancy months or even a year before the clinical
manifestation of malignancy is an indispensable clinical tool.
3.3 Serum-TK1 Prognostic potential
In many haematological and solid tumors especially those for which sTK1 levels are significantly elevated,
sTK1a and sTK1p is a prognostic factor. Responses to chemotherapy and/or surgery are often associated with
sTK1 levels. For example, Zhang et al. compared preoperative sTK1p in bladder carcinoma patients with
postoperative sTK1 levels at 1 week, 1, 3, and 6 months (J. Zhang et al., 2006). They reported sTK1p levels
were 66% lower at 1 week postoperatively, reached normal levels (<2 pM) at 1month, and remained in the
normal range until the study ended at 6 months (J. Zhang et al., 2006). Similarly, Li et al. reported in nonmetastatic NSCLC patients, 1 month postoperative sTK1p levels decreased significantly by 45%, compared to
preoperative sTK1 (H. X. Li et al., 2005). Conversely, they reported that sTK1p levels in metastatic NSCLC
patients did not significantly change 1 month postoperative. This same trend was seen with metastatic and nonmetastatic breast cancer surgery patients (Q. He et al., 2000). Zou et al. saw the same significant decrease in
postoperative sTK1 levels for gastric cancer although only sTK1p, not sTK1a, decreased (Liu et al., 2011; Zou
et al., 2002).
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Pre-treatment sTK1 levels have been shown to predict which patients are most likely to respond to
treatment. Di Raimondo et al. demonstrated that 83% of CLL patients with complete response (CR) or partial
response (PR) to fludarabine initially had sTK1a levels < 10 U/L. On the other hand, only 45% of the CLL
patients with sTK1a levels ≤ 10 U/L had CR or PR, a significant difference compared to patients above this
threshold (Di Raimondo et al., 2001). Alternatively, during chemotherapeutic treatment, sTK1 levels fluctuate
depending on a patient’s response. Robertson et al. tracked the sTK1a levels of 10 advanced breast cancer
patients bimonthly during the first 6 months of their hormone therapy (Robertson et al., 1990). Five patients
responded positively to treatment with a resulting decline in their sTK1a levels while five patients progressed
while on their treatment and showed increased sTK1a levels. Interestingly, Liu et al. reported no overall
significant decrease in sTK1p of gastric patients after 1, 2, or 4 cycles of chemotherapy unless patients were
sorted according to their response. Only those patients with either CR, PR or no recurrence had significantly
decreased sTK1p levels after cycle 2 of chemotherapy, although the levels began to decline after cycle 1. The
patients with either disease progression or recurrence during chemotherapy had increased sTK1p levels (Liu et
al., 2011). To determine what happens immediately after treatment, Pan et al. compared pre-treatment sTK1p
levels to levels at day 1 and 28 of chemotherapy. They reported a significant increase in sTK1p levels at day 1
followed by a significant decrease correlated with response at day 28, at which time it reached normal sTK1p
levels (Pan et al., 2010). This peak in sTK1p during the first day after chemotherapy may be explained by TK1
being released from cancer cells as a result of cell death, which is an indication of effective treatment (Pan et
al., 2010). Di Raimondo et al. supported this conclusion as they showed sTK1a levels were correlated with
those of beta2-microglobulin and lactate dehydrogenase, indicators of tumor cell turnover (Di Raimondo et al.,
2001). Xu et al. similarly reported that sTK1p levels in a variety of malignancies increased by 40-50% during
the first month of treatment and subsequently decreased to normal levels (X. H. Xu et al., 2008). The same
trends in which sTK1a and sTK1p levels reflect response to treatment have been confirmed in many cancers
including lung, esophageal, head and neck, thyroid, leukemia, and colon cancer (Y. Chen et al., 2010; O.
Topolcan et al., 2005; Votava et al., 2007).
In addition to cancer monitoring, sTK1 levels are indicative of survival. In CLL patients, high sTK1
levels were associated with a 22% survival rate compared with a 65% survival rate in patients with low sTK1
(Di Raimondo et al., 2001; Fujiwaki et al., 2001; Konoplev et al., 2010). Similarly, in operable breast cancer
patients high sTK1 is associated with shorter disease specific survival (DSS), local recurrence free survival
(RFS) and distant relapse free interval (Broet et al., 2001; Elfagieh et al., 2012). In renal cell carcinoma and
non-Hodgkin lymphoma high sTK1 indicated a lower 5-year RFS (Nisman, Yutkin, et al., 2010; Pan et al.,
2010). Similarly, Liu et al. determined that monitoring sTK1 levels during the first 2 months of palliative
treatment for advanced gastric cancer was more indicative of progression free survival (PFS) and RFS
compared to initial baseline sTK1 (Liu et al., 2011). In advanced breast cancer patients, the 5-year disease free
survival (DFS) with high sTK1 was 21%, with a median of 23 months; while patients with low sTK1 had 56%
DFS, with a median >30 months (Z. H. Huang et al., 2012). sTK1 was also able to subcategorize
nonsmoldering CLL patients at risk for rapid disease progression. Hallek et al. reported nonsmoldering patients
with high sTK1a had PFS as expected, 8 months. On the other hand, nonsmoldering patients with low sTK1a
had a PFS of 49 months, more typical of smoldering CLL, which indicated that sTK1 was able to identify
which nonsmoldering CLL patients were at risk for rapid progression (Hallek et al., 1999).
Early detection of recurrence and elevated risk for recurrence are also associated with increased sTK1
levels. Generally, sTK1 levels are significantly higher, 50-60%, in patients with recurrent tumors compared
with primary tumors (Z. Li et al., 2010; K. L. O'Neill et al., 2007; X. H. Xu et al., 2008). Huang et al.
estimated that patients were 6-7 times more likely to get recurrence if sTK1p levels were high after
neoadjuvant therapy (Z. H. Huang et al., 2012). He et al. also reported that 63% of breast cancer patients who
recurred up to 18 months after surgery, had higher sTK1p but not elevated sTK1a (Q. He et al., 2006). In
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addition to indicating a risk for recurrence, sTK1 levels begin to rise months before the clinical manifestation
of recurrent tumors. For example, Votava et al. reported that sTK1a began to elevate 1 month before a
diagnosis of recurrence in childhood leukemia patients (Votava et al., 2007). Svobodova et al. estimated that
sTK1a levels increased at least 3 months before recurrence as detected by imaging methods, although the
increase could be seen sometimes as early as 6 or 9 months before the clinical manifestation of recurrence
(Svobodova et al., 2007). Since recurrent tumors play a major role in cancer mortality, detecting recurrence
through sTK1 levels several months earlier could help give clinicians an upper hand towards effective
treatment.
Currently, there are nine FDA-approved cancer biomarkers including CEA, CA15-3, and CA19-9
(Rhea & Molinaro, 2011). CA15-3 is a breast cancer biomarker which is known for its poor sensitivity and
specificity, but is approved for monitoring breast cancer treatment and recurrence (Rhea & Molinaro, 2011).
CA15-3 and sTK1p levels were compared in breast cancer patients preoperatively and 3 months
postoperatively (Q. He et al., 2006). sTK1p, but not CA15-3, was significantly increased with recurrence
which indicated that sTK1 may be a better marker for breast cancer recurrence than CA15-3 (Q. He et al.,
2006). Although CEA is primarily approved for colon cancer monitoring, it is also elevated in breast cancer
patients (Chevinsky, 1991). Elfagieh et al. compared CEA, CA15-3, and sTK1 levels for breast cancer
prognosis (Elfagieh et al., 2012). They determined that increased levels of CEA, CA15-3, and sTK1 were
found in 62%, 70%, and 78% of breast cancer patients respectively. They also reported a combined evaluation
of all 3 biomarkers increased the sensitivity to 90%, which indicated that the most accurate diagnosis of breast
cancer can be determined using all 3 biomarkers (Elfagieh et al., 2012). In a comparison study of colon cancer,
only sTK1a levels, not CEA or CA19-9 levels, changed during chemotherapy treatment (O. Topolcan et al.,
2005). Clearly, sTK1 levels provide more clinically relevant prognosis for monitoring cancer patients than
several of the FDA-approved biomarkers currently in clinical use. Although sTK1 is also a worthy screening
tool, its efficacy in cancer monitoring and prognosis fills a clinical need which may provide the driving force
to propel TK1 into clinical use.
3.4 Tumor-TK1 Diagnostic potential
In addition to efficacy as a serum biomarker, TK1 has valuable potential as a means of diagnosis and prognosis
in tumor tissue. TK1 expression in tumor tissue (tTK1) has repeatedly been shown to be a more relevant
proliferation marker than PCNA. Although both TK1 and PCNA were overexpressed in malignant tissue
compared with normal tissue, only TK1 was significantly increased with both grade and stage (Y. Mao et al.,
2002; C. Wu et al., 2003; J. Wu et al., 2000). This was true for advanced breast, liver, thyroid, and colon
cancer, although PCNA was associated with stage in colon cancer (Y. Mao et al., 2002; C. Wu et al., 2003; J.
Wu et al., 2000). Ki67 and BrdU labeling are two other proliferation markers which have been compared with
TK1. In 2009, Gasparri reported that TK1 expression during the cell cycle occurs earlier than either Ki67 or
BrdU labeling, referred to as an activated G1 state, which is high in TK1 and low in Ki67 (Gasparri et al.,
2009). Virtually all comparison studies reported a strong positive correlation between Ki67 and tTK1
expression in both malignant and pre-malignant conditions such as breast atypical ductal hyperplasia tissue
(ADH), NSCLC, and infiltrating ductal breast carcinoma (Brockenbrough et al., 2009; Guan et al., 2009; Q.
He et al., 2004). There are slight differences between Ki67 and tTK1 expression. Mao et al. reported a
significant difference between tTK1 and Ki67 expression in lung adenocarcinoma tissue but not squamous cell
carcinoma. In adenocarcinoma tissue, the significant increase of tTK1 expression resulted mostly from staining
of stage 2 and grade 2 tumors (Y. Mao et al., 2005). Since there were also tumors which expressed Ki67 only,
a combination of tTK1 and Ki67 was recommended for routine testing (Y. Mao et al., 2005). This
recommendation was confirmed by He et al. who reported that the combination of tTK1 and Ki67 expression
in breast carcinoma tissue detected the most tumors (Q. He et al., 2004). Zacchetti et al. ranked the
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proliferation markers according to their performance in breast tumors in this order PCNA<Ki67<BrdU
labeling (Zacchetti et al., 2003). Although this study did not include tTK1, tTK1 is elevated earlier in the cell
cycle than Ki67 or BrdU, and can identify tumors which Ki67 misses, indicating that tTK1 may be a more
accurate proliferation marker (Guan et al., 2009).
Similar to sTK1 levels, tTK1 overexpression is an early event and can help identify pre-malignancies.
Guan et al. demonstrated that tTK1 was positive in 80-90% of ADH, ductal carcinoma in situ (DCIS) and
invasive ductal carcinoma (IDC) but only positive in less than 5% of usual ductal hyperplasia (UDH) (Guan et
al., 2009). This indicated that ADH, a pre-malignancy, was at increased risk for progression and was
significantly higher in tTK1 expression compared to UDH (Guan et al., 2009). The increase of TK1 early in
the cell cycle, referred to as an activated G1 state, is also indicative of the early increase of tTK1 (Gasparri et
al., 2009). Although the overexpression of tTK1 in pre-cancerous tissue has been confirmed, Alegre et al.
demonstrated that tTK1 was not elevated in prostate hyperplasia tissue (Alegre et al., 2012, 2013). However,
since sTK1 is elevated in some cases of prostate hyperplasia, further work is needed to understand the clinical
significance of elevated TK1 in prostate hyperplasia (Chen et al., 2011; S. Huang et al., 2011).
It is well established that tTK1 expression is significantly higher, compared to corresponding normal
tissue, in breast, liver, thyroid, lung, colon, kidney, esophageal, uterine, prostate, and stomach cancer (Alegre
et al., 2013; Y. Mao et al., 2005; Y. Mao et al., 2002; C. Wu et al., 2003; J. Wu et al., 2000). Occasionally, the
TK1 antibody used can affect the results of the study. Mao et al. found differences when NSCLC tissue was
stained with a c-terminal mouse monoclonal (mAb) and c-terminal chicken anti-TK1 antibody (Y. Mao et al.,
2005). Although there was not a significant difference in percentage of tTK1 positive tumors, the distribution
of staining varied. The mAb primarily stained stage 2 and grade 2 tumors, with a decrease in tTK1 positive
staining in more advanced tumors, while the chicken antibody showed the opposite result with the highest
degree of staining in the more advanced tumors (Y. Mao et al., 2005). Although some reports using serum and
tumor tissue have indicated that TK1 in kidney cancer is significantly elevated compared to normal tissue,
Mizutiani et al. reported tTK1 activity was 4 fold higher in normal kidney tissue compared to renal cell
carcinoma (Mizutani et al., 2003). In a subsequent study, they confirmed these findings and to date, this
remains the only tissue reportedly higher in normal tissue than corresponding malignant tissue (Luo et al.,
2010). These discrepancies remain unclear although a thorough analysis of the differences among the
antibodies used could shed light on this controversy. Nevertheless, standardization of scoring and a full
characterization of the TK1 antibodies would enable clinicians to make needed comparisons as TK1 transitions
from the bench to the bedside.
Recently a derivative of TK1 was also used to stain tumor tissue. XPA-210 is a c-terminal TK1
peptide fragment which includes amino acid 210 (Aufderklamm et al., 2012). Typically tTK1 is a cytoplasmic
marker, but XPA-210 expression as detected by a mAb, is located primarily in the nucleus which is more
comparable to Ki67 (Gakis et al., 2011). Although there have only been 3 studies involving XPA-210, the
trends for prostate and renal cell carcinoma appear to confirm corresponding studies with tTK1 (Aufderklamm
et al., 2012; Gakis et al., 2011; Kruck et al., 2012). Regardless of which antibody or peptide fragment of TK1
is used, it remains clear that tTK1 is significantly overexpressed in a variety of tumor tissue, including some
cases of pre-malignancy.
3.5 Tumor-TK1 Prognostic potential
tTK1 corresponds with sTK1 in that both have diagnostic and prognostic potential. Just as sTK1 correlated to
survival, recurrence, and treatment, similar trends are seen with tTK1. Xu et al. reported that high tTK1
expression was associated with significantly worse 5 year survival in pT1 lung adenocarcinoma patients (Y.
Xu et al., 2012). Additionally, Romain et al. reported tTK1 expression in node-negative breast cancer tumors
was an independent factor for metastatic free survival and DFS (Romain et al., 2000). Their subsequent study
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similarly reported high tTK1 increased the risk of developing distant recurrence and therefore, tTK1 was able
to identify which node-negative patients were at a high risk for metastasis (Romain et al., 2001). Aufderklamm
et al. similarly reported that higher XPA-210, a fragment of TK1, was associated with shorter time to
recurrence and metastasis (Aufderklamm et al., 2012).
In addition to tTK1 expression, the TK1 activity of tumor tissue (tTK1a) is also associated with
patient prognosis. Demeter et al. reported the activity of tTK1a was 12-fold higher in ovarian carcinoma, but
Mizutani et al. reported only a 2-fold increase for bladder carcinoma relative to normal controls (Demeter et
al., 2001; Mizutani et al., 2002). Mizutani et al. also showed that those with low tTK1a had longer RFS
(Mizutani et al., 2002). Similarly, O’Neill et al. reported that tTK1a levels in the initial primary breast tumor
were associated with recurrence, in that those with recurrence also initially had significantly higher sTK1a
levels (K. L. O'Neill, McKelvey, et al., 1992). In a study by Foekens et al. the initial sTK1 activity level also
affected the duration of response in advanced breast cancer (Foekens et al., 2001). For tumors with low,
intermediate or high tTK1a, the duration of response was 23, 15, and 13 months respectively (Foekens et al.,
2001). In renal cell carcinoma, the tTK1a levels are inversely associated with sensitivity to 5-fluorouracil
(5FU), which is likely associated with TK1’s role in DNA repair, as previously discussed (Mizutani et al.,
2003).
Unfortunately there is a need to correlate a patient’s tTK1 and sTK1 levels to determine if they are
redundant. Both sTK1 and tTK1 generally share the same trends in diagnosis and prognosis. TK1 levels are
elevated very early including in pre-malignancy in both serum and tumor tissue. Additionally, increased TK1
in serum and tumor is associated with worse prognosis and disease progression including recurrence. Finally,
serum and tumor TK1 appear more accurate and indicative of patient prognosis when compared with other
biomarkers including proliferation markers. The efficacy and utility of monitoring TK1 levels both in
malignant and healthy individuals remains clear.
3.6 TK1 Therapeutic potential
Although the primary clinical value of TK1 is in its diagnostic and prognostic potential, TK1 also has limited
therapeutic potential. TK1 plays an intricate role in DNA repair and maintaining dTTP levels, as discussed
previously. Franciullino et al. demonstrated that overexpression of TK1leads to desensitization of tumor cells
to 5FU (Fanciullino et al., 2006). Somewhat surprisingly, they also showed that TK1 does not limit the
production of 5FU-monophosphate, indicating as previously discussed, that TK1 is involved in DNA repair.
Due to the redundant nature of TK1, Di Cresce et al. targeted both TK1 and thymidylate synthase (TS), the
salvage and de novo pathways respectively, with siRNA which successfully re-sensitized tumors to 5FU
treatment (Di Cresce et al., 2011). A study by Wakazono et al. demonstrated that a decrease in dTTP levels
made tumor cells hypersensitive to treatment with alkylating agents (Wakazono et al., 1996). Since TK1 and
TS both contribute to dTTP levels, this appears to explain the importance simultaneous knockdown of TK1
and TS to re-sensitize tumors.
TK1 is also used in gene therapy although instead of hTK1, herpes simplex virus TK (HSV-TK) is
utilized. A virus-based vector delivers the HSV-TK to gliomas or other tumors in connection with ganciclovir
treatment, a harmless prodrug (J. X. Zhang et al., 2010). HSV-TK acts as a suicide gene by cleaving
ganciclovir into a toxic compound (J. X. Zhang et al., 2010). This system works for a variety of tumors and has
been reviewed thoroughly elsewhere (Oh et al., 2010). Since HSV-TK varies considerably from human TK1 in
structure, function and characteristics in malignancy, we will not discuss it further in this review.
3.7 TK1 Imaging: Positron Emission Tomography (PET)
PET imaging is a clinical tool used to help determine tumor metabolism. Flurodeoxyglucose (FDG) is the
approved substrate for PET imaging. Unfortunately, FDG-PET is limited in that metabolism is complex and
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FDG only assesses one aspect of cellular metabolism (Shields, 2012). In an effort to understand more about
tumor proliferation to enable more accurate prognosis, 3’-deoxy-3’-fluorothymidine (FLT) and other substrates
were created (Agarwal et al., 2013; Bading & Shields, 2008; Struthers et al., 2010). Katz et al. reported that
FLT, but not FDG, predicted response to TRAIL and sorafenib treatment in tumors with functional p53 (Katz
et al., 2011).
FLT is phosphorylated by TK1, producing FLT-MP which is then trapped in cells. Unfortunately,
FLT-PET is not currently in clinical use. This is most likely because there is tremendous controversy regarding
whether FLT uptake into cells correlates with proliferation, measured by TK1 and/or Ki67 levels. Shinomiya et
al. recommended that FLT should not be used as a measure of proliferation since FLT phosphorylation did not
reflect either tTK1 expression or tTK1 mRNA levels (Shinomiya et al., 2013). Zhang et al. agreed as they
reported low FLT uptake with corresponding high TK1 and Ki67 expression in tumor tissue (C. C. Zhang et
al., 2012). Several others have agreed that either TK1 or Ki67 expression is not associated with FLT uptake
(Benz et al., 2012; Lee et al., 2011; McKinley et al., 2013). Conversely, Brockenbrough et al. reported that
FLT uptake was correlated with tTK1 and Ki67 expression but not tTK1a (Brockenbrough et al., 2011). Still
others have reported FLT uptake strongly correlated with tTK1a and/or tTK1 expression (Barthel et al., 2005;
Kameyama et al., 2011; Rasey et al., 2002). McKinley et al. has tried to reconcile this controversy. They
reported that FLT uptake corresponds with tumor proliferation, as a function of thymidine salvage pathway
utilization, but not general proliferation as measured by Ki67 expression (McKinley et al., 2013). Furthermore,
FLT uptake did not distinguish between tumors which primarily utilized the thymidine salvage pathway (TK1)
and those which utilized the de novo thymidine pathway (McKinley et al., 2013).
Despite the numerous studies which have shown FLT-PET’s prognostic potential and possible
advantages over FDG-PET, we still do not adequately understand the connection between proliferation and
FLT-PET. Unless resolved with a clear consensus, this controversy will continue to bar FLT-PET from being
utilized clinically.

4 Conclusion
Overall, TK1 is a clinically relevant cancer biomarker which is significantly elevated in serum and tissue of
cancer patients. Structurally, TK1 is primarily found as an active tetramer or dimer of dimers. As an active
tetramer, TK1 is responsible for converting dT to dTMP in a cell-cycle dependent manner. By extension, TK1
is also responsible for maintaining adequate dTTP levels for DNA synthesis. In tumor cells TK1 plays a
pivotal role in DNA repair and affects a tumor’s sensitivity to chemotherapy treatment. During the cell cycle,
TK1 rapidly increases in late G1 and peaks in S phase. This rapid increase is primarily due to ATP availability
and a concentration-dependent dimer to tetramer switch. Following the S phase peak, TK1 is rapidly degraded
by the APC/C-Cdh1 complex which recognizes a KEN box on the c-terminus of TK1.
In malignancy, TK1 exits the cell as a very stable, high molecular weight form which appears to be a
TK1 aggregate, 3-7 times larger than active TK1. TK1 is significantly elevated early in the progression of
normal cells to malignancy. In fact, in serum and tumors, TK1 is found elevated in some cases of pre-cancer.
Furthermore, TK1 is elevated in serum and tumor tissue of virtually all types of cancer. In addition to the
diagnostic potential of TK1, TK1 also has beneficial prognostic potential. In particular, high sTK1 or tTK1
levels are associated with worse prognosis, including shorter survival and an increased risk for recurrence. In
fact, sTK1 elevates 1-9 months prior to the clinical manifestation of recurrence. As a tool for monitoring a
patient’s response to treatment, sTK1 decreases significantly in patients with complete response or partial
response. On the other hand, sTK1 continues to increase in patients who continue to see disease progression or
recurrence. In addition to diagnostic and prognostic potential, TK1 also has limited therapeutic potential.
Although most of its therapeutic potential lies with HSV-TK as a suicide gene, TK1 can also be used as a
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means of re-sensitizing tumors to chemotherapeutic agents. Finally, TK1 is also used as a potential imaging
tool through FLT-PET, as a means of determining the extent of a tumor’s proliferation. Clearly, TK1 has vast
clinical potential, especially as a screening and monitoring tool for cancer patients. As more accurate and
robust methods of detection for TK1 arise, TK1 will no doubt be a powerful clinical tool in the coming years.
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Abstract: Prognostic markers play an important role in our understanding of tumors and how to treat them.
Thymidine kinase 1 (TK1), a proliferation marker involved in DNA repair, has been shown to have independent
prognostic potential. This prognostic potential includes the novel concept that upregulation of serum TK1 levels is
an early event in cancer development. This same effect may also be seen in tumor tissue. In order to demonstrate
that TK1 upregulation is an early event in tumor tissue formation, tissue arrays were obtained and stained for TK1
by immunohistochemistry. Using a progressive breast tissue array, precancerous tissue including breast adenosis,
simple hyperplasia, and atypical hyperplasia stained positive for TK1 expression. Different stages of breast
carcinoma tissue also stained positive for TK1 including nonspecific infiltrating duct, infiltrating lobular, and
infiltrating duct with lymph node metastasis carcinomas. This indicates that TK1 upregulation is an early event in
breast carcinoma development, and may be useful in identifying precancerous tissue. Further work is needed to
better understand the differences seen between TK1 positive and negative tissues.

1. Introduction
Studies have shown that the early detection of breast cancer leads to better patient
prognosis and a greater five-year survival rate. Diagnostic and prognostic markers play a
key role in classifying tumors and determining the best treatment plan for a patient. The
most widely used and established prognostic markers for breast cancer recurrence are
tumor size, tumor grade, lymph node involvement, and tumor hormone receptor status.
These indicators, although well established, are all related to tumor aggressiveness.
Recent evidence has shown that proliferation markers, such as Ki-67 and proliferating
cell nuclear antigen (PCNA), may have independent prognostic value [1–3]. Although
these proliferation markers have potential, recent studies indicate that thymidine kinase 1
(TK1), another marker associated with proliferation, may be a better prognostic marker
than either Ki-67 or PCNA [4, 5].
Thymidine kinase 1 (TK1) has been studied extensively, primarily as a diagnostic
biomarker for a variety of cancer types. TK1 is a nucleotide salvage pathway repair
enzyme that is primarily responsible for the phosphorylation of thymidine to thymidine
monophosphate. TK1 is associated with proliferating cells and is primarily elevated
during S phase [6, 7]. As a biomarker, higher serum TK1 activity levels correlate with a
more advanced cancer stage and grade [8–10]. Serum TK1 levels also show prognostic
potential as their levels help predict future relapse at the time of primary diagnosis in
breast and colorectal cancer patients [11, 12].
Similar trends have been found between tumor tissue and TK1 expression levels. One
study demonstrated that breast cancer patients who later showed recurrence initially had
higher primary tumor TK1 levels when compared to those patients who did not show
recurrence [13]. Furthermore, breast cancer patients with either high or intermediate TK1
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activity in their tumors showed rapid disease progression and poorer prognosis as
compared to patients with low TK1 activity in their tumors [14]. Tumor TK1 levels,
similar to serum TK1 levels, also correlate with both stage and grade [15]. Tumor TK1
has also been compared with both Ki-67 and PCNA. Although there is a significant
correlation between PCNA and TK1 staining of breast cancer tissue, TK1 showed a
significant correlation with stage and grade while PCNA did not, indicating that TK1
might be a more accurate marker for diagnosis and prognosis [4]. Similarly, there is a
significant correlation between Ki-67 and TK1 in breast cancer tissue when compared to
normal tissue; however, due to early upregulation of TK1 as compared with Ki-67, TK1
may be a more accurate prognostic marker [16, 17].
TK1 upregulation as an early event of cancer is a novel concept that has been addressed
by only a few recent studies. One such study involving a health screening of 8,135 people
found that 89.2% of persons with elevated serum TK1 levels had diseases linked to risk
for pre-/early cancerous progression, including one individual who developed liver
carcinoma 13 months after the health screening [18]. Similar studies have also shown that
recurrence can be detected by elevated serum TK1 levels as early as 1–6 months before
the clinical onset of relapse [19]. These studies show the early nature of serum TK1
levels in tumor development. This study seeks to determine whether, similarly to serum
TK1, tumor TK1 upregulation is an early event in tumor development and may aid in the
identification of precancerous tissue.

2. Materials and Methods
2.1. Patients and Specimens
Tissue arrays containing tissue from normal (n = 56), adenosis (n = 22), and breast
carcinoma (n = 97) patients as well as a progressive breast array (Cybrdi Inc., Frederick
MD) were analyzed for TK1 expression. Breast carcinoma tissue included simple
carcinoma (n = 30), infiltrating duct carcinoma (n = 41), medullary carcinoma (n = 12),
scirrhous carcinoma (n = 11), and infiltrating lobular carcinoma (n = 3).
2.2. Immunohistochemistry
Tissue arrays were stained using an anti-TK1 mouse monoclonal antibody (CB001),
which we previously demonstrated to be highly specific to TK1 [20]. Using this antibody,
histological slides were stained using the following procedure. Briefly, formalin-fixed
paraffin-embedded specimens were prepared by deparaffinization and rehydration. To
retrieve antigenicities of TK1, specimens were boiled in 0.01 M sodium citrate buffer (pH
6.0) for 12 minutes and allowed to cool at room temperature for 20 minutes. The
endogenous peroxidase activity was blocked by immersion in 3% H2O2 in methyl alcohol
at room temperature for 20 minutes. The slides were then washed in phosphate-buffered
saline (PBS; pH 7.2) and blocked in 10% normal horse serum for 30 minutes. After
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blocking, the slides were incubated at room temperature for 3 hours with either anti-TK1
mouse monoclonal antibody (diluted 1 : 100) or isotype control (0.6 μg/μL, mouse IgG,
Upstate Company, 12-371). Slides were washed with PBS and then incubated with a
biotin-conjugated anti-mouse secondary antibody (ABC kit, Vector Lab Inc.) at room
temperature for 30 minutes. After PBS washing, slides were incubated for 30 minutes, at
room temperature, with Streptavidin-Peroxidase (ABC Kit, Vector Lab Inc.) and then
washed again in PBS. Diaminobenzidine (Vector Lab Inc.) was used as a chromagen, and
the slides were counterstained with haematoxylin.
2.3. Statistical Analysis and Scoring
Specimens were scored by three pathologists, and a consensus score of positive, weak
positive, or negative was compiled. A positive score indicated cytoplasmic staining of
TK1 in 5–25% of tumor cells. If some signal was detected but was insignificant when
compared to the isotype control, it was given a weak positive score. A negative score
indicated no staining. All blood vessels and fibrous tissue cores were excluded from
statistical analysis. A chi-square test of independence was applied to compare the scores
of normal and malignant tissues. Due to the limited number of cases in the progressive
breast array, no statistical analysis on this array could be performed. Differences
with 𝑃 < 0 . 0 5 (two-sided) were regarded as statistically significant.

3. Results and Discussion

TK1 expression was found to be significantly different (𝑃 < 0 . 0 0 1) between normal
breast and breast carcinoma tissue. A total of 73 breast carcinoma tissues (79%) were
positive for TK1 expression while only 18 normal breast tissues (36%) scored positive.
Breast tissue was also stained using an isotype control (mouse IgG, Upstate Company),
and all breast tissue was found to be negative. Since these normal tissues were retrieved
from the margins around a tumor and were considered pathologically normal, we sought
to determine if tissue from noncancerous individuals yielded similar results. Interestingly,
there was no TK1 staining in any breast tissue obtained from noncancerous individuals,
called FDA-approved true normal tissue (data not shown). Therefore, these 18 TK1
positive normal tumor margins may not be false-positive results, but rather precarcinoma
tissue, which is considered pathologically normal tissue by current standards. Further
work is needed to better understand these potential differences.
TK1 expression was also found to be significantly different (𝑃 = 0 . 0 1 3) between the
different types of breast carcinoma tissue. A chi-square test of independence was applied
to compare the scores of the various types of breast carcinoma tissue. The Pearson chisquare value was 22.452, using 10 degrees of freedom, and the two-sided P-value was
0.013. The results are summarized in Table 1 and typical staining can been seen in
Figure 1. In summary, infiltrating lobular carcinoma and scirrhous carcinoma tissues all
stained positive for TK1, while 66–83% of simple, infiltrating duct, and medullary
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carcinoma tissues stained positive for TK1. Further studies with larger sample sizes may
further elucidate the differences between these tissue types.
Table 1: TK1 scoring of different types of carcinoma tissue.
Diagnosis

Negative

Weak positive

Positive

Total

Simple carcinoma
Infiltrating duct carcinoma
Medullary carcinoma
Scirrhous carcinoma
Infiltrating lobular carcinoma

3
11
4
0
0

2
4
0
0
0

25
26
8
11
3

30
41
12
11
3

Total

18

6

73

97

(a)

(b)

(c)

(d)
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(e)
FIGURE 1: TK1 breast tissue staining. (a) No TK1 staining was found in most normal duct
tissue. TK1 positive staining could be found in the cytoplasm of tumor cells of (b) simple
carcinoma, (c) infiltrating duct carcinoma, (d) medullary carcinoma, and (e) sclerosing
carcinoma tissues.

In addition to the TK1 positive breast carcinoma tissues, 4 breast adenosis tissues (22%)
were also found to be positive for TK1 expression. These 4 positive precancerous tissues
were the first indication that TK1 expression may be an early event in tumor
development. To pursue this hypothesis, we obtained a progressive breast array. This
progressive breast array included tissue from different tumor developmental stages, such
as normal, adenosis, and atypical hyperplasia, moderate atypical hyperplasia, severe
hyperplasia, nonspecific infiltrating duct carcinoma, infiltrating lobular carcinoma, and
infiltrating duct carcinoma with lymph node metastasis. The results are summarized in
Table 2 and typical staining can be seen in Figure 2. The proliferating epithelial cells of
some cases of breast adenosis were positive for TK1 expression as well as breast tissue
with simple or atypical hyperplasia. As previously seen, most breast carcinoma tissues
were also positive for TK1 expression while no breast tissue stained positive with an
isotype control. It appears from this progressive array that since TK1 is found in
precancerous tissue, TK1 upregulation is an early event in breast tumor development.
These results support the previous conclusion that in some cases, there may be a
difference between true normal tissue from noncancerous patients and the pathologically
normal tumor margins. Further studies are needed to elucidate the differences between
both the normal tumor margins and precancerous tissues that were positive for TK1 and
those that were negative. Perhaps, the prognostic value of TK1 may be of help in
identifying those precancerous tissues which are of greatest risk to the patient. Therefore,
TK1 expression is an early event in tumor development and may aid in the identification
of precancerous tissue.
Table 2: TK1 scoring of breast progressive array.
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Pathological types of breast tissues

Negative/positive

Normal tissues
Breast adenosis
Sclerosing adenosis
Atypical hyperplasia
Infiltrating lobular carcinoma
Infiltrating carcinoma
Infiltrating carcinoma with lymph node metastasis

−
−
−/+
−/+
+
+
+

(a)

(b)

(c)

(d)
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(e)

(f)

(g)
FIGURE 2: Breast progressive array staining. (a) No TK1 staining was found in normal lobule
breast tissue. However, TK1 staining was found in proliferating duct epithelial cells of
precancerous tissue including, (b) breast adenosis, (c) breast adenosis with mild atypical
hyperplasia of duct epithelium, and (d) moderate atypical hyperplasia of duct epithelium.
Positive TK1 staining in the cytoplasm of tumor cells was also found in cancerous tissue such as,
(e) intraductal carcinoma, (f) infiltrating duct carcinoma, and (g) medullary carcinoma tissues.

4. Conclusion
The aim of this study was to determine if TK1 upregulation is an early event in tumor
development. From the progressive breast array, it can be seen that in many cases of
breast cancer, TK1 is upregulated in precancerous tissue and remains elevated in
correlation to cancer stage. This confirms earlier research that indicated that elevated
TK1 levels correlated with early recurrence. Although not elevated in all tumors, TK1
appears to be upregulated as an early event in most tumors and therefore can possibly be
used in connection with other diagnostic and prognostic techniques to improve patient
33

outcome. These results also indicate that the TK1 positive pathologically normal tumor
margins may in fact be tumor cells that have escaped pathological identification. This
preliminary research may indicate that TK1 can be used to identify possible malignant
cells, which have evaded pathological detection during surgical removal. Unfortunately
due to the anonymity of these patient samples, we have been unable to determine if TK1
positive tumor margins are of clinical significance. Further research would be required to
establish if these TK1 positive cells are in fact a result of the tumor tissue. Overall, it
appears that TK1 has diagnostic and prognostic potential in identifying breast tumor
tissue as well as precancerous tissues. The ability to identify tumor tissue during the early
stages of development is of significant value. Therefore, the histological identification of
tumors utilizing TK1 suggests promising prognostic and diagnostic potential in breast
cancer tissue.
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Abstract: Thymidine Kinase 1 (TK1) is traditionally a serum biomarker which is elevated in the early stages of
malignancies. TK1 is a DNA repair enzyme which is typically associated with proliferation. In serum, TK1 is
elevated in a stage-like manner and increases as the disease advances. As a well-characterized serum biomarker,
relatively little work has been done to establish it as a tumor biomarker. However, tumor TK1 reflects many of the
same trends that can be seen with serum TK1. Specifically, tumor TK1 is an early event in tumor progression and
increases with grade and stage. This study seeks to demonstrate that, similar to serum TK1, tumor TK1 is a valuable
indicator of malignancy in the most common types of cancer in men. In this study we used a highly specific
monoclonal antibody to TK1 to histologically stain 10 different types of carcinoma tissue and corresponding normal
tissue. We found that TK1 is a good marker for malignancy and is significantly overexpressed in cancers compared
to normal controls in lung, colon, prostate, esophagus, stomach, liver, and kidney tissues. Slight differences were
found in the staining pattern among various types of lung cancer although virtually all types showed significantly
higher TK1 staining compared to normal tissue. Additionally, TK1 expression in prostate carcinoma was
significantly higher than from normal tissue, and correlated with an increase in stage. Overall, it is clear that TK1 is
a valuable cancer marker in a wide variety of solid tumors and may be considered a universal cancer marker.
1. Introduction
Cancer is the second leading cause of death in the United States but is the number one cause of death in individuals
ages 40 to 79 years (Siegel, Naishadham, & Jemal, 2013). In men, the two most prevalent cancer sites which
contribute to cancer mortality are lung and prostate. Together these account for approximately 38% of cancer deaths
in men (Siegel et al., 2013). Although many biomarkers have been identified in the hopes of reducing cancer
mortality rates, few have been successful. However, thymidine kinase 1 (TK1) may have independent potential to
reduce cancer mortality rates through early detection.
TK1 is a biomarker which is involved in DNA repair and is upregulated during S phase (He, Skog, & Tribukait,
1991). It is considered a proliferation marker and is often compared with Ki67 and/or proliferating cell nuclear
antigen (PCNA). Several studies have shown that TK1 is more useful as a proliferation marker than either Ki67 or
PCNA (Guan et al., 2009; He et al., 2004; Z. H. Huang et al., 2012). TK1 has primarily been studied as a diagnostic
and prognostic tool found in the serum of cancer patients. TK1 is elevated in a stage-specific manner in a variety of
solid and hematological malignancies (Aufderklamm et al., 2012). For example, TK1 has been established as a
serum biomarker in breast cancer, lung cancer, colon cancer, malignant melanoma, gastric cancer, non-Hodgkin’s
lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and acute myeloid leukemia in addition to
several other cancer types (Li et al., 2010; Liu et al., 2011; O'Neill, Zhang, Li, Fuja, & Murray, 2007; Wu et al.,
2013; Xu et al., 2009). TK1 is elevated in the very early stages of cancer and has even been found elevated in the
precancerous stages (S. Huang et al., 2011). In fact, in a health screen of 35,365 individuals 0.8% had elevated
serum TK1, and 8.8% of those with elevated TK1 went on to develop new malignancies or had progression of their
pre-malignancies (Chen et al., 2011). Recent studies have also found that TK1shows similar trends in tumors. In
breast cancer patients, TK1 was overexpressed in atypical ductal hyperplasia, precancerous lesions, and also in
carcinoma tissue (Alegre, Robison, & O'Neill, 2012; Guan et al., 2009). Although TK1 has been well-characterized
as a serum biomarker and similar trends are seen with tumor TK1, this study seeks to compare TK1 expression in a
variety of solid tumors. In particular, we compare TK1 expression within the two most common types of cancer in
men: prostate and lung, to possibly establish TK1 as a candidate marker for the major forms of cancer in men.
2. Methods
2.1 Patient Samples
All the following arrays were analyzed for TK1 expression using a highly-specific anti-TK1 monoclonal antibody
(CB001) (O'Neill, Buckwalter, & Murray, 2001). A multi-organ tissue array containing carcinoma tissue from 9
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different organs of 30 individuals and normal controls of 7 different organs from 48 individuals were analyzed for
TK1 expression. Carcinoma tissue included liver (n=6), stomach (n=6), esophagus (n=6), kidney (n=6), uterus
(n=5), colon (n=6), brain (n=6), muscle (n=6), and lung (n=6). Normal tissue included liver (n=6), stomach (n=6),
esophagus (n=6), kidney (n=6), colon (n=6), rectum (n=6), and lung (n=6). Prostate tissue arrays included tissue
from prostate carcinoma (n=32), normal prostate (n=17) and prostate hyperplasia (n=6). True normal tissue arrays
included tissue from 100 individuals and 34 organs (Cybrdi Inc, Frederick MD). Lung tissue arrays included lung
cancer tissue (n=376) from 172 individuals and normal lung tissue (n=63) from 29 individuals (Cybrdi Inc,
Frederick MD). Lung cancer tissue included small cell carcinoma (n=37), large cell carcinoma (n=19),
adenocarcinoma (n=26), squamous cell carcinoma (n=36), sarcoma (n=2), adenosquamous cell carcinoma (n=4),
bronchioloalveolar carcinoma (n=5), mucinous adenocarcinoma (n=1), mesothelioma (n=2), undifferentiated
carcinoma (n=4), neuroendocrine carcinoma (n=3), and papillary carcinoma (n=1).
2.2 Immunohistochemistry
Each of the tissue arrays were stained using an anti-TK1 monoclonal antibody (CB001) and an isotype control
(mouse IgG, Upstate Company, 12-371). The staining procedure is as previously described (Alegre et al., 2012).
Briefly, the tissues were deparafinized and rehydrated. After antigen retrival with 0.01M Sodium Citrate buffer (pH
6.0) and blocking for endogenous peroxidase activity, slides were blocked (10% normal horse serum) and then
incubated for 3 hours with CB001 or isotype control (0.6ug/ml). After washing, slides were incubated with biotinconjugated anti-mouse secondary antibody (Vector Labs Inc.), washed again, and incubated with StreptavidinPeroxidase (ABC Kit, Vector Labs Inc.). Slides were developed using diaminobenzidine (Vector Labs Inc.) and
counterstained with haematoxylin.
2.3 Statistical Analysis and Scoring
Each tissue specimen was scored by three independent pathologists and given a consensus score of negative, weak
positive, or positive. Additionally, the lung tissue arrays were scored using a fourth category of strong positive. In
each case, a positive score was associated with staining in 5-25% of tumor cells. A weak positive score indicated
that although some staining was present, it was insignificant compared to the isotype control. A negative score was
associated with no staining. Additionally, a strong positive score for the lung arrays indicated >25% of tumor cells
showed TK1 expression. Statistical analysis of the tissue specimens included a chi square test of independence and
p<0.05 (two-sided) was regarded as statistically significant.
3. Results
3.1 A Universal cancer marker: TK1expression
TK1 expression was evaluated using a highly specific monoclonal antibody in histological slides of 9 different
carcinoma tissues from 30 individuals including brain, esophagus, stomach, colon, liver, lung, kidney, uterine, and
muscle. TK1 expression was also evaluated in 8 different normal tissues from 48 individuals including esophagus,
stomach, liver, uterine, colon, rectum, lung, and kidney. Three independent pathologists scored each tissue and TK1
cytoplasmic staining was detected in hepatocellular carcinoma, clear cell carcinoma of kidney, uterus
rhabdomyosarcoma, esophageal squamous cell carcinoma, and adenocarcinoma of the uterus, stomach, colon, and
lung (Figure 1). On the other hand, weak positive TK1 expression was found in 3 cases of meningioma indicating
that although some signal was present, it was insignificant compared to the isotype control. No TK1 staining was
detected in normal esophagus, stomach, and kidney tissue (Figure 1). Weak positive TK1 expression was found in
normal lung, liver, colon, and rectum tissues (Figure 1). There was no significant difference between carcinoma and
normal uterus tissue. Unfortunately, only two normal uterine tissues were available for this analysis and more tissue
is needed to confirm these findings. TK1 expression was significantly higher in tumor tissue of the esophagus,
stomach, colon, liver, lung and kidney compared to normal tissue (Table 1). Each of the tissues was also stained
with an isotype control (mouse IgG, Upstate Company), and all tumor and normal tissue was negative.
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Figure 1: TK1 multi-organ tissue staining.
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Cytoplasmic TK1 staining was found in A) colon adenocarcinoma, C) esophageal squamous cell carcinoma, E) lung
adenocarcinoma, and G) kidney clear cell carcinoma tissues. None or weak TK1 staining can be found in normal B)
colon, D) esophagus, F) lung, and H) kidney tissues.
Table 1: TK1 staining in normal and carcinoma tissue.

Liver

Normal
Carcinoma
Stomach
Normal
Carcinoma
Esophagus Normal
Carcinoma
Kidney
Normal
Carcinoma
Uterus
Normal
Carcinoma
Colon
Normal
Carcinoma
Lung
Normal
Carcinoma

Weak
Negative Positive Positive
0
6
0
0
0
6
6
0
0
1
3
2
4
1
0
0
2
4
6
0
0
0
0
6
0
0
2
0
2
3
0
6
0
3
1
2
0
5
0
0
2
4

Total
6
6
6
6
5
6
6
6
2
5
6
6
5
6

Significance
0.001
0.014
0.016
0.001
0.29
0.014
0.022

Interestingly, the normal tissue included in this study was initially taken from the margins around the tumor. These
margins from cancer patients were considered normal using current pathological methods. However, recent studies
have indicated that the normal microenvironment surrounding a tumor in many cases is altered and has lost its
normal regulation (Alegre et al., 2012; Farmaki et al., 2012; Niu et al., 2012). Previous studies have suggested that
this may help explain some TK1 positive staining in these normal tumor margins (Alegre et al., 2012). Therefore,
we obtained normal tissue from 100 noncancerous individuals, called true normal tissue, which included 34 true
normal organs (Cybrdi Inc, Frederick MD). TK1 cytoplasmic staining was found in adrenal gland cells, germ cells
of the seminiferous tubules of the testis, and hematopoietic cells of the bone marrow (Figure 2). Weak background
staining was seen in tubular cells of the kidney, cardiac and striated muscle cells, salivary gland duct cells, mucous
secreting cells in small intestine and stomach, and transitional cells of the ureter and bladder (Figure 2). No other
true normal organs stained positive for TK1, including those normal tumor margins which previously showed weak
positive staining for TK1.
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Figure 2: TK1noncancerous true normal staining.
No TK1 staining could be found in A) true normal colon, and B) true normal uterus tissue. Cytoplasmic TK1
staining was found in C) true normal bone marrow and D) true normal adrenal gland. Weak positive TK1 staining
was found in E) true normal cardiac tissue and F) true normal kidney tissue.
3.2 A marker for the #1 cancer killer in men: TK1 and lung cancer
Since the majority of cancer mortality in men is due to lung cancer, we investigated the link between TK1 staining
and lung cancer more thoroughly. TK1 expression was evaluated in 376 lung cancer tissue cores representing 172
individuals and 63 normal lung cores from 29 individuals. Samples represented a variety of lung cancer diagnoses
including small cell carcinoma, large cell carcinoma, adenocarcinoma, squamous cell carcinoma, adenosquamous
cell carcinoma, bronchioloalveolar carcinoma, mucinous adenocarcinoma, undifferentiated carcinoma,
neuroendocrine carcinoma, papillary carcinoma, mesothelioma, and sarcoma. Combining all lung cancer tissues,
there is a highly statistically significant difference between TK1 expression in lung cancer and normal lung tissue
(p<0.0001). In this study, we only had access to one mucinous adenocarcinoma and one papillary carcinoma, and
both cases showed positive TK1 expression, but further samples should be tested to confirm this finding.
Neuroendocrine carcinoma tissues were not significantly different in TK1 expression compared to normal lung
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tissue. All other lung cancer groups showed significantly higher TK1 expression compared to normal controls
including small cell carcinoma, large cell carcinoma, adenocarcinoma, squamous cell carcinoma, undifferentiated
carcinoma, mesothelioma, bronchioloalveolar carcinoma, adenosquamous cell carcinoma, and sarcoma (Table 2).
There was also a statistically significant difference in TK1 expression between small cell lung cancer and non-small
cell lung cancer (p<0.0001) in which non-small cell lung cancer exhibited higher TK1 expression. Additionally,
squamous cell carcinoma had significantly higher TK1 expression compared to adenocarcinoma tissues (p<0.0001),
but squamous cell carcinoma was not significantly different from large cell carcinoma. Although each of the
individual lung cancer diagnosis groups differed slightly, all were significantly higher than normal lung tissue,
indicating that TK1 may be a valuable marker for lung cancer.
Table 2: TK1 staining in various types of lung cancer.

Small Cell Carcinoma
Large Cell Carcinoma
Adenocarcinoma
Squamous Cell Carcinoma
Bronchioloalveolar Carcinoma
Adenosquamous Cell Carcinoma
Undifferentiated Carcinoma
Neuroendocrine Carcinoma
Sarcoma
Mesothelioma
Mucinous Adenocarcinoma
Papillary Carcinoma
Normal Lung

Weak
Negative Positive
11
26
5
6
13
5
3
10
0
3
0
1
0
2
0
0
0
1
0
0
0
0
0
0
24
4

Positive
0
1
8
18
2
2
2
2
1
2
1
1
1

Strong
Positive
0
7
0
5
0
1
0
1
0
0
0
0
0

Total
37
19
26
36
5
4
4
3
2
2
1
1
29

Significance
0.0018
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.0002
0.0755
0.025
0.0016
-

3.3 A marker for the #2 cancer killer in men: TK1 and prostate cancer
Prostate cancer is responsible for a large portion of cancer mortality in men, second only to lung cancer. Due to this
high prevalence in both mortality and incidence, we sought to determine whether TK1 histological staining could
also be used as a marker for prostate cancer. TK1 expression was evaluated in 57 prostate tissues which represented
20 individuals. Each individual was represented by 3 different tissue cores including normal, hyperplasia, or
carcinoma tissues. Each tissue was also stained with an isotype control (mouse IgG, Upstate Company) and all these
isotype-stained tissues were negative. The majority of prostate adenocarcinoma tissue exhibited TK1 cytoplasmic
positive staining which was significantly different compared to either normal or hyperplasia tissues (p<0.0001)
(Table 3). Additionally, TK1 expression increased as prostate adenocarcinoma advanced from grade 1 to grade 3
(p=0.004) (Figure 3). This confirms our previous findings that TK1 is a valuable marker of malignancy and is
expressed in the very early stages of cancer.
Table 3: TK1 staining in prostate cancer.

Normal
Hyperplasia
Adenocarcinoma
Adenocarcinoma grade 1
Adenocarcinoma grade 2
Adenocarcinoma grade 3

Negative
9
6
5
0
3
0

Positive
8
0
27
1
4
22

Total
17
6
32
1
7
22

Significance

<0.0001

0.004
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Figure 3: TK1 staining in prostate cancer.
No TK1 staining was found in A) normal prostate and B) prostate hyperplasia. Cytoplasmic TK1 staining was found
in C) prostate carcinoma grade 2 and D) prostate carcinoma grade 3. There was a significant increase in TK1
expression from prostate carcinoma grade 1 to grade 3.
4. Discussion
This is the first study to do an overall comparison and analysis of TK1 expression among a variety of malignant
tissues. It is clear that TK1 is a good marker for malignancy as it is significantly increased in a variety of carcinoma
tissues. For example, as the data in Table 1 indicates, there is a highly significant difference between normal and
carcinoma tissues for virtually all organ types. From this we determined that TK1 is a good marker of malignancy in
at least seven of the most common types of cancer, including lung, colon, prostate, esophagus, stomach, liver, and
kidney. Typically, if TK1 is expressed in normal tissue, it is very weak and insignificant compared to the isotype
control. Although there was no significant difference in TK1 expression between normal and carcinoma uterine
tissues in our study, several other studies have demonstrated that TK1 can be used as a marker for uterine
malignancy (Shintani, Urano, Takakuwa, Kuroda, & Kamoshidai, 2010). Additionally, TK1 as a marker for breast
cancer and hematological malignancies, has been well-established by previous studies (Aufderklamm et al., 2012).
Together, this indicates that TK1 appears to be a good universal marker for cancer among both solid and
hematological malignancies.
Previous studies have demonstrated that TK1 overexpression is an early event in cancer, both in the serum of cancer
patients and in primary tumors (Guan et al., 2009; S. Huang et al., 2011). Interestingly, our study revealed that TK1
is expressed in some normal tissue (Table 1). However, this tissue was taken from the tumor margins and considered
normal using current pathology standards. On the other hand, the same organ tissue taken from noncancerous
individuals, called true normal tissue, did not express TK1. Due to the early diagnostic nature of TK1, it may be that
these normal tumor margins may in fact be precancerous lesions which are considered normal by current pathology
standards. Perhaps, these cells which normally remain undetected may play a role in the development of recurrent
lesions. It would be interesting to follow the patients with TK1 positive tumor margins to determine if those patients
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later relapsed or showed worse prognosis. Unfortunately, no follow-up data was available and we could not
determine the clinical significance of TK1 positive tumor margins.
Of particular note, TK1 expression is a good marker for both lung and prostate cancer, the two most frequently
diagnosed and leading causes of cancer-related deaths in men (Siegel et al., 2013). Although there are slight
differences in the staining patterns of lung cancer, virtually all types of lung cancer had higher TK1 expression
which was highly significantly different compared to normal lung tissues (Table 2). Prostate cancer tissues showed
similar trends and even showed increasing TK1 expression from grade 1 to grade 3 prostate carcinoma tissues.
5. Conclusion
Our results indicate that TK1 expression is significantly higher in malignancy compared to normal tissue. TK1
appears to have potential as a tumor marker in a wide variety of malignancies, including at least seven of the most
common types, and thus may be a useful universal cancer marker.
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Abstract: Introduction—Lung cancer is known for its late-stage diagnosis, ultimately leading to high mortality.
Thymidine kinase 1 (TK1) is an early detection biomarker, elevated in malignancies including lung cancer. Elevated
TK1 is an early event which is associated with risk of malignant progression. In this study, we propose a sensitive
and specific TK1 immunoassay for the early detection of lung cancer.
Methods—Forty pre-operable lung cancer and 18 normal serums were collected. TK1 levels were determined by the
traditional TK radioassay and a novel TK1 enzyme-linked immunosorbent assay (ELISA). Additionally, 17 sputum
samples were analyzed for TK1 activity.
Results—TK1 was significantly elevated in all lung cancer and stage 1, node-negative patients compared to controls
(p<0.001 and p=0.009, respectively). The best cut-off value was 4.9 nM. This gave an area under the curve of 0.792
and 0.828 for early stage and all lung cancer respectively. The sensitivity and specificity for all lung cancer patients
was 82.4 and 83.3, respectively. There was no significant difference in TK1 activity between lung cancer and
healthy controls. This indicated that TK1 concentration is a more sensitive and accurate indicator of lung cancer
than TK1 activity. TK1 activity is significantly higher in lung cancer sputum compared to controls, demonstrating a
possible TK1 lung cancer specific test.
Conclusions—Overall, TK1 is significantly elevated in the lung cancer serum and sputum of patients. This novel
TK1 ELISA is both sensitive and specific for early stage and advanced lung cancer. This assay may aid in the early
detection of lung cancer.

Introduction
Lung cancer accounts for the most cancer-related deaths in men and women [1]. Currently there are no
FDA-approved biomarkers for the early detection or monitoring of lung cancer [2]. The only
recommended early detection tool for lung cancer is a low-dose spiral CT scan. The National Lung
Screening Trial reported 20% reduced mortality for high-risk individuals screened with spiral CT scans
[3]. Despite its promising potential, there are many disadvantages to this screening method including cost,
invasiveness, and exclusivity. In this study we propose a novel early detection test which may overcome
many of these limitations. We demonstrate that this early detection enzyme-linked immune sorbent assay
(ELISA) for thymidine kinase 1 (TK1) is highly sensitive and specific for the diagnosis of stage 1, nodenegative lung cancer as well as more advanced lung cancer patients.
TK1 is a well-established cancer biomarker which is elevated in the serum and tumor tissue of
many hematological and solid tumors including lung cancer [4-6]. TK1 is efficacious as both a diagnostic
and prognostic tool since changes in serum TK1 levels reflect a patient’s response to treatment, and risk
for recurrence [7-9]. TK1 is elevated in the very early stages of malignancy. In fact, in a health screen of
8,135 individuals, 1.1% of individuals had elevated TK1 levels in which nearly 90% of those with
elevated TK1 had pre-cancerous diseases [10]. Included in those non-cancerous individuals with elevated
TK1 was one individual who developed liver carcinoma 13 months following the reported high TK1
level. Several other studies have confirmed that TK1 is elevated in pre-malignancy. Guan et al.
demonstrated that TK1 is significantly elevated in atypical ductal hyperplasia (ADH), ductal carcinoma in
situ, and invasive ductal carcinoma compared to normal breast tissue [11, 12]. However, they reported
that TK1 was not significantly elevated in usual ductal hyperplasia tissue (UDH). Since TK1 was elevated
in some pre-cancerous diseases such as ADH but not others, UDH, this indicated that perhaps elevated
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TK1 is associated with pre-cancerous diseases which have an increased risk of progression. This appears
to be the case and has been confirmed in several large health screens including one with 35,365
individuals and one with 11,880 individuals [13, 14]. In these health screens, individuals with premalignant diseases were found in both the elevated TK1 and normal TK1 groups although a significantly
higher percentage of individuals with pre-malignant diseases had elevated TK1. The pre-malignant
patients with elevated TK1 were more likely to show disease progression within 5 to 72 months compared
to pre-malignant patients with normal TK1 (8.8% vs 0.2%) [14]. Therefore, non-cancerous individuals
with elevated TK1 levels had 3-5 fold increased risk of developing malignancies [14].
Lung cancer is frequently diagnosed in the advanced stages, and TK1 is elevated in lung cancer
and other malignancies very early. Therefore, we sought to develop a simple TK1 ELISA to help identify
lung cancer patients much earlier. We hope this will be an efficacious alternative to the spiral CT scan
and help to decrease lung cancer mortality rates. In this study, we demonstrate a sensitive and specific
TK1 ELISA in which stage 1, node-negative lung cancer patients and more advanced lung cancer patients
have significantly elevated serum TK1 levels compared to healthy individuals. Furthermore, we
demonstrate that this TK1 ELISA is more sensitive than traditional methods of detecting TK1 in lung
cancer patients.
Materials and Methods
Patient samples. Serum samples from 40 pre-operable lung cancer patients were obtained from
University of Colorado medical center. Serum samples from 18 healthy individuals were obtained from
community volunteers near Brigham Young University. Additionally, 17 sputum samples (lung cancer
sputum, n=15, normal sputum, n=2) were obtained from the University of Colorado. All samples were
collected according to IRB guidelines and all patients signed consent forms. Upon collection, samples
were immediately stored as aliquots at -80ºC until analysis.
TK1 ELISA. Serum samples were analyzed using a previously described direct ELISA protocol with
slight modifications [15]. The anti-TK1 antibody used was a highly specific mouse monoclonal antibody
(produced by our lab) which reacts against an internal fragment of TK1, amino acids 46-145, designated
A74. Briefly, 50 µl samples were diluted in carbonate buffer, pH 9.6 and allowed to absorb to 96-well
ELISA plates overnight at 4ºC. Wells were then washed four times with phosphate-buffered saline (PBS),
pH 7.4 and blocked with 2% BSA diluted in T20 PBS Blocking Buffer (Thermo Fisher Scientific) for one
hour at room temperature. Wells were again washed and then incubated for one hour at room temperature
with HRP conjugated anti-TK1 antibody diluted in block. Wells were again washed and developed with
1-Step Ultra TMB (Thermo Fisher Scientific) and quenched with sulfuric acid. Samples were analyzed
using Synergy HT Microplate Reader (Bio-Tek) at 450 nm. Samples were run in duplicate and confirmed
with at least 2 independent experiments. The standard curve was constructed using recombinant human
TK1 at varying concentrations diluted in carbonate buffer. The average of the serum samples and the
recombinant TK1 standard curve was used to calculate TK1 concentration in the serum samples.
TK1 Radioassay. The TK radioassay was optimized for human serum samples and run as previously
described [16]. The reaction mix contained 10 mM Tris-HCl pH 7.6, 2 mM DTT, 5 mM MgCl2, 5 mM
NaF, 5 mM ATP, and 5 µM [3H]-dThd. Samples were run as quadruplets and the data was confirmed with
at least 2 independent experiments. The average of all runs was used for statistical analysis. Sputum
samples were also analyzed using the TK radioassay. Since cell extracts often have both TK1 and TK2
activity, sputum samples were run separately with ATP and CTP. ATP is utilized by both TK1 and TK2
while CTP is only utilized by TK2 [17]. Therefore, TK1 activity in sputum samples is reported as % TK1.
Since TK2 is not found in significant quantities in serum samples, this is not necessary for TK1 activity in
serum [16].
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TK1 Dot Blot. Serial dilutions of serum or recombinant TK1 (10 µl) were applied to a nitrocellulose
membrane (Bio-Rad) and allowed to dry for 1 hour at room temperature. The membrane was then
blocked with 5% non-fat dry milk (NFDM) diluted in tris-buffered saline (TBS) for one hour at room
temperature. Following 3 washes with 0.1% Tween T20 in TBS (TBS-T), the membrane was incubated
with A74, a highly specific anti-TK1 monoclonal antibody, diluted in block for one hour at room
temperature. The membrane was washed five times with TBS-T and incubated with goat anti-mouse HRP
conjugated secondary antibody absorbed against human, bovine, horse, rabbit, and swine (Jackson
ImmunoResearch) for one hour at room temperature. The membrane was washed again and developed
using Immun-Star WesternC Chemiluminescence kit (Bio-Rad).
Immunohistochemistry. TK1 staining of lung cancer and normal tissue was performed as previously
described [12]. Briefly, tissue slides were deparaffinized, rehydraded and antigenicities were retrieved
using 0.01M sodium citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked, and washed
prior to incubation with 10% normal horse serum. Primary antibody, a highly specific anti-TK1
monoclonal antibody (CB001), was added for 3 hours at room temperature. Following the primary
antibody, slides were washed, incubated with biotin-conjugated secondary antibody, washed and then
incubated with streptavidin-peroxidase (ABC kit, Vector Labs Inc). Slides were then washed, developed
using diaminobenzidine (Vector Labs Inc), and counterstained with haematoxylin.
Statistical Analysis. The diagnostic power of this TK1 ELISA was determined by analyzing the area
under the receiver operating characteristics (ROC) curve. The best cut-off value was determined by
maximizing sensitivity and specificity. The data is presented as mean ± the standard deviation (SD) and
median ± interquartile range (IQR). Student t-test and Wilcoxon rank-sum test were used to determine
statistical significance, which was set at p< 0.05. Sensitivity, specificity, positive predictive value,
negative predictive value, and odds ratio (± 95% CI) were reported. All analyses were performed using
SPSS software.
Results
Patient characteristics

Forty pre-operable lung cancer patients’ sera were collected prior to any treatment. Sixteen patients were
stage 1, node-negative (pT1a and pT1b), and 18 patients were diagnosed with stage 2 lung cancer (Table
1). Additionally, 6 patients had secondary lung tumors arising from the colon, esophagus, cervix, or
prostate. Most lung tumors were adenocarcinomas (n=16) although several patients were diagnosed with
squamous cell (n=8) and adenosquamous cell carcinoma (n=2) (Table 1). The median age of lung cancer
patients was 68, range 22-88. There was a fairly high percentage of never smokers (n=9) in our data-set
compared to the national average of never-smoker lung cancer patients, 28% and 10-15% respectively
[18]. We chose to focus on pre-operable, typically stage 1 and 2, lung cancer patients as a means of
detecting lung cancer in its early stages. Overall, we feel our patient population represents a good
sampling of early stage, pre-operable lung cancer patients.
Table 1: Lung cancer patient characteristics
Diagnosis:
Adenocarcinoma
Squamous cell carcinoma
Adenosquamous cell carcinoma
Other lung cancer
Metastasis to lung
Non-cancer

16
8
2
8
6
18
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Lung cancer by stage:

Stage 1
Stage 2
Metastasis to lung

16
18
6

Age and Sex:

Median age in years (range)
Female
Male

68 (22-88)
17
23

Cancer patient
smoking history:

Never smoker
Former smoker
Current smoker

9
14
17

A74: anti-TK1 antibody specificity

In order to confirm that A74 can accurately detect native TK1 in tumor tissue as well as serum, we stained
lung adenocarcinoma and squamous cell carcinoma tissues for TK1 expression using a highly specific
monoclonal antibody (CB001) appropriate for TK1 immunohistochemical detection (Figure 1). TK1
expression was clearly elevated in lung cancer tissue with minimal or no staining in normal lung tissue.
This confirmed several other studies which have reported significantly elevated TK1 expression in lung
carcinoma tissue, including pT1 adenocarcinoma tissue, compared to normal lung [4, 6]. Furthermore, we
determined through dot blot that A74 TK1 antibody detected native recombinant TK1 as well as native
cancer serum TK1 (Figure 1). Native western blot analysis confirmed that A74 detected native serum
TK1 in its expected molecular weight, 100-700 kDa (data not shown). This highly specific anti-TK1
antibody is unique in its ability to identify un-reduced serum TK1. This unique property allowed us to
proceed and develop an immunoassay without reducing agents.

A

B

C
D
Figure 1: TK1 antibody specificity.
A) TK1 expression, detected by CB001, is elevated in squamous cell carcinoma, grade 2-3, but B) little or no TK1
expression is found in normal lung tissue. A74, a mouse monoclonal TK1 antibody, detects C) recombinant TK1,
serial dilutions 707-22 ng/ml, and D) serial dilutions of native cancer serum TK1 by dot blot.
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TK1 ELISA-all lung cancer cases

We used recombinant TK1 as the positive control to generate a standard curve for this novel TK1 ELISA
(Figure 2). Forty pre-operable lung cancer patients, stage 1 and 2, were collected for TK1 analysis. TK1
concentration was analyzed using the TK1 ELISA while TK1 activity was determined using the
traditional TK radioassay, previously optimized for human serum samples [16]. The mean (SD) of TK1
concentration in pre-operable lung cancer patients and healthy controls was 5.6 (1.32) nM and 4.5 (0.84)
nM, respectively. The median (IQR) for TK1 concentration in lung cancer and healthy sera was 5.8 (5.06.3) and 4.4 (3.9-4.6) nM, respectively. There was a highly statistically significant difference between
TK1 concentration in lung cancer patients and healthy controls as determined by the TK1 ELISA for both
the Wilcoxon rank-sum and student t-test, p<0.001. The mean (SD) of TK1 activity as determined by the
traditional TK radioassay for lung cancer and healthy controls was 8,866 (1030) cpm and 9,575 (1579)
cpm, respectively. There was no statistically significant difference in TK1 activity between lung cancer
and healthy sera (p=0.69). Since our cancer samples represent very early stage lung cancer patients, we
are not surprised that the TK radioassay could not distinguish major differences in TK1 activity levels.
This indicates that our novel TK1 ELISA is more sensitive and accurate than the traditional TK1
radioassay, especially for early stage lung cancer patients.
The best cut-off value for lung cancer patients (stage 1 and 2) as determined by ROC analysis
was 4.9 nM. At this cut-off value, there was a highly statistically significant difference between serum
TK1 concentration in lung cancer and normal controls, p<0.0001. The AUC was 0.828 (Figure 3). The
sensitivity and specificity (95% CI) at this cut-off value was 82.4 (65.5-93.2) and 83.3 (58.6-96.4),
respectively (Figure 3). The positive predictive value and negative predictive value was 90.3 (74.3-98.0)
and 71.4 (47.8-88.7), respectively. The odds ratio at this same cut-off value was 23.333 (5.097-106.812),
indicating that patients with a serum TK1 concentration above 4.9 nM had 23 fold increased risk of
having lung cancer than those with serum TK1 levels <4.9 nM.
Two pre-operable lung cancer patients were excluded from this study because they were
pretreated with chemoradiation and had less than 10% viable tumor. Since all lung cancer samples were
analyzed blind, it was particularly interesting once the patient details were revealed to find an explanation
for their lower than expected TK1 levels. Initially these patients were diagnosed with stage 3 lung cancer
but after presurgical treatment, their levels had dropped in the range of normal and stage 1, node-negative
patients. The TK1 concentrations of these two samples were 5.382 and 5.139 nM, which were excluded
from the 40 pre-operable lung cancer analysis as a result of their pretreatment.
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Figure 2: TK1 ELISA Standard Curve.
This standard curve was used to calculate TK1 concentrations in lung cancer and normal serum samples.

A

B

Figure 3: TK1 ELISA ROC curves.
A) The AUC for stage 1, node-negative lung cancer patients is 0.792 with a sensitivity and specificity of 75.0 and
83.3, respectively. B) The AUC for all lung cancer cases is 0.82 with a sensitivity and specificity of 82.4 and 83.3,
respectively.
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Figure 4: Box plot of TK1 distribution in lung cancer and healthy serum.
The median and interquartile range is represented by the box and center line. The maximum and minimum values,
excluding outliers, are represented by the vertical lines. A) There is a highly significant difference in TK1
concentration in preoperable lung cancer serum compared with normal controls (p<0.001), but no significant
difference in TK1 activity (B). C) There is a significant difference in TK1 concentration in stage 1, node-negative
and stage 2 lung cancer patients compared to controls (p=0.007 and p<0.001, respectively). There is no significant
difference in TK1 concentration between stage 1 and stage 2 lung cancer patients. D) There is no significant
difference in TK1 activity among stage 1, stage 2 lung cancer and normal controls.
TK1 ELISA-stage 1, node-negative lung cancer

In an effort to determine if our novel TK1 ELISA could detect significant differences in the earliest
diagnosed stage of lung cancer, stage 1, node-negative, we separated the forty lung cancer sera into stage
1 and stage 2 patients (Table 1). The mean (SD) of TK1 concentration in stage 1 (pT1) lung cancer, stage
2 lung cancer, and healthy sera was 5.3 (0.98), 6.2 (1.47) and 4.5 (0.84) nM, respectively. The median
(IQR) of TK1 concentration in stage 1, stage 2 lung cancer, and healthy sera was 5.4 (4.7-6.1), 5.9 (5.26.8), and 4.4 (3.9-4.6) nM, respectively. According to the student t-test and Wilcoxon rank-sum test, there
was a statistically significant difference in TK1 concentration between stage 1 lung cancer and healthy
sera (p=0.009 and p=0.007 respectively). There was also a significant difference between stage 2 lung
cancer and healthy serum according to both the t-test and rank-sum test (p<0.001). In either the t-test or
rank-sum test, there was not a significant difference between stage 1 and stage 2 lung cancer sera (p=0.06
and p=0.11 respectively). The mean (SD) of TK1 activity in stage 1, stage 2 lung cancer, and healthy sera
was 8,816 (968), 8,850 (1075), and 9,574 (1579) cpm, respectively. According to the student t-test, there
was not a significant difference between any of the groups including stage 1 and stage 2, stage 1 and
normal, or stage 2 and normal sera. This confirms our previous finding that the novel TK1 ELISA is more
sensitive and accurate than the traditional radioassay.
The best cut-off value as determined by ROC analysis for stage 1 lung cancer and normal sera
was also 4.9 nM (p=0.002). The AUC was 0.792 (Figure 3). The sensitivity and specificity (95% CI) was
75.0 (47.6-92.7) and 83.3 (58.6-96.4) respectively. The positive and negative predictive values were 80.0
(51.9-95.7) and 79.0 (54.4-94.0), respectively. The odds ratio (95% CI) at this cut-off value was 14.999
(2.800-80.352) indicating that patients with TK1 concentrations above 4.9 nM had 15 fold increased risk
of having lung cancer, stage 1.
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Of the 40 lung cancer pre-operable lung cancer sera, 6 sera were secondary lung tumors.
According to the student t-test, these secondary lung tumors had significantly higher TK1 concentration
levels compared with normal sera (p=0.0005) but not a significant difference in TK1 activity levels
(p=0.196). There was not a significant difference in TK1 concentration or TK1 activity between primary
and secondary lung tumors.
TK1 in sputum samples

Since TK1 is not a lung cancer specific marker, we sought to determine a method by which we could
detect TK1 in lung cancer specifically. We obtained and blindly analyzed the TK1 activity in 17 sputum
samples. Unfortunately, the sample volume was limited so only the % TK1 activity, not TK1
concentration, was determined. TK1 activity in cell extracts is often confounded by TK2 activity since
ATP acts as a donor for both enzymes. However, CTP is only utilized by TK2 [17]. Therefore, we
reported TK1 activity as a percentage of total TK activity, to eliminate confounding TK2 activity. This
was only necessary for sputum cell extract since serum TK1 activity is not confounded by TK2 [16]. The
% TK1 mean (SD) of the lung cancer sputum and normal sputum samples was 57.9% (13.8) and 32%
(11.2), respectively (Figure 4). Even though only 2 normal sputum samples were available for this study,
there was a statistically significant difference between lung cancer and normal sputum samples, p=0.014.
A larger sample size, especially including normal sputum, is needed to confirm these preliminary results.
Nevertheless, it appears that sputum TK1, possibly in connection with serum TK1, could be used for the
early detection of lung cancer.
80

% TK1 activity in Sputum
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Lung cancer Sputum

Normal Sputum

Figure 5: TK1 in Sputum.
The % TK1 activity in lung cancer sputum is significantly higher compared with normal sputum (p=0.014). Since
normal sputum availability was limited, a larger sample size may be needed to confirm these preliminary results.

Discussion
Previous studies have demonstrated that TK1 is a powerful diagnostic and prognostic tool in the serum of
cancer patients. Unfortunately, the clinic has not yet harnessed its potential because of challenges
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associated with developing a clinical relevant method of detection. A TK1 ELISA, such as the one
proposed here, overcomes limitations of using radioisotopes in the traditional TK radioassays and
problems associated with specificity, sensitivity, and reproducibility. Since the ELISA platform is
commonly used in the clinic, a TK1 ELISA could be adapted to other high-throughput immunoassays
currently in clinical use.
This study introduces a novel TK1 ELISA which is both sensitive and specific. In addition to
detecting significant differences in TK1 between advanced lung cancer and those of healthy individuals,
there is a significant difference in TK1 levels of stage 1, node-negative lung cancer patients and healthy
individuals. TK1 concentrations, as detected by the TK1 ELISA, show significant differences between
TK1 in lung cancer and healthy individuals while TK1 activity does not. This indicates that our novel
TK1 ELISA is more sensitive and accurate than traditional TK radioassays. This confirms other studies
which have reported that in lung, breast, gastric, rectal, colorectal, brain cancer, leukemia, lymphoma, and
hepatoma, TK1 protein concentration is more sensitive than TK1 activity [5].
In ROC analysis, the sensitivity is analogous to the true positive results or in other words, a lung
cancer patient has TK1 levels above the cut-off value, as expected. A sensitivity of 100% would indicate
that even asymptomatic lung cancer patients in the earliest stages of the disease, would have TK1
elevated above the cut-off value. On the other hand, specificity is analogous to true negative results. A
specificity of 100% would have no false positives, such that every individual with TK1 above the cut-off
value would have lung cancer. The two ROC curves representing either all lung cancer cases or only
stage1, node-negative individuals had sensitivities and specificities of 82.4, 83.3 and 75.0, 83.3,
respectively. A sensitivity or specificity between 90-99% could not be used for our data set since very few
patients had concentrations above these cut-off values. In subsequent follow-up studies with larger sample
sizes and more advanced tumors, it will likely be possible to have a sensitivity or specificity >90%.
However, the AUC, sensitivity and specificity of the TK1 ELISA is comparable to other TK1
immunoassays which indicates this novel TK1 ELISA may be a reliable method of detection [14, 16, 19].
Furthermore, the positive predictive value represents the probability of lung cancer in individuals
with a TK1 level above the cut-off value. On the other hand, the negative predictive value represents the
probability that an individual with a TK1 level below the cut-off value does not have cancer. The positive
and negative predictive values of either all lung cancer cases or only the earliest lung cancer stages were
90.3, 71.4 and 80.0, 79.0, respectively. Several studies have indicated that elevated TK1 is associated
with risk for disease progression [10, 11, 13, 14, 20]. Some tumors have a lower risk of progression and a
corresponding low TK1 level [21]. This is one possible explanation for why some individuals in our study
with lung cancer had lower TK1 levels. This would contribute to a lower negative predictive value. A
long-term follow-up study of lung cancer individuals with low preoperative TK1 levels would be needed
to determine if their baseline serum TK1 levels could predict which individuals have an increased risk for
disease progression. Although this study has not been conducted, similar studies have indicated that
tumor TK1 expression and tumor TK1 activity can predict which tumors have an increased risk for
recurrence [21-23].
One disadvantage of using a TK1 ELISA for the early detection of lung cancer is that TK1 is
elevated in a variety of malignancies and is not lung cancer specific. Sputum is frequently taken from
potential lung cancer patients to aid in lung cancer diagnosis. In this study, we demonstrated that TK1
activity is significantly elevated in lung cancer sputum compared to normal sputum. This indicates that
perhaps screening for elevated TK1 in sputum can be an early indication of lung cancer.
Overall, it is clear that this novel TK1 ELISA is both sensitive and specific for the early detection
of lung cancer. Further studies are needed to validate these exciting preliminary results. We believe this
ELISA will aid in the early detection of lung cancer, the early detection of recurrent lung tumors, and
monitoring a patient’s response to treatment. TK1 as detected by the traditional radioassay has already
proved efficacious in these areas. Therefore, we believe that this novel TK1 ELISA will similarly prove
effective in monitoring a patient’s response to treatment.
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Abstract: Cancer prevention is rapidly emerging as a major strategy to reduce cancer mortality. In the field of breast
cancer significant strides have recently been made in the understanding of underlying preventative mechanisms.
Currently three major strategies have been linked to an increase in breast cancer risk: obesity, lack of physical
exercise, and high levels of saturated dietary fat. As a result, prevention strategies for breast cancer are usually
centered on these lifestyle factors. Unfortunately, there remains controversy regarding epidemiological studies that
seek to determine the benefit of these lifestyle changes. We have identified crucial mechanisms that may help clarify
these conflicting studies. For example, recent reports with olive oil have demonstrated that it may influence crucial
transcription factors and reduce breast tumor aggressiveness by targeting HER2. Similarly, physical exercise reduces
sex hormone levels which may help protect against breast cancer. Obesity promotes tumor cell growth and cell
survival through upregulation of leptin and insulin-like growth factors. This review seeks to discuss these underlying
mechanisms and more behind the three major prevention strategies as a means of understanding how breast cancer
can be prevented.

Introduction
Breast cancer is among the most frequently studied diseases in oncology (Siegel, Naishadham et
al. 2012). In fact, breast cancer accounts for nearly 1 in 3 female cancers, and consequently is the
number one most frequently diagnosed cancer in women. Fortunately, the 5-year relative survival rate
of breast cancer patients has increased to 77-90% today (Siegel, Naishadham et al. 2012). However,
despite recent advances in our understanding of cancer, breast cancer incidence rates have generally
remained stable (Siegel, Naishadham et al. 2012). These statistics show that while there has been great
improvement in detection, treatment options, and survival, there remains a great need to reduce breast
cancer incidence rates through prevention.
There are several factors which have shown promise in reducing breast cancer incidence rates.
Some of the most popular preventative measures relate to lifestyle choices, especially changes in diet.
Despite the fact that the American Cancer Society recommends consuming a diet high in fruits and
vegetables, there remains some controversy regarding the role of diet in cancer prevention (Kushi,
Doyle et al. 2012). Most of this controversy comes from inconsistent results obtained from studies
involving either single foods or single nutrients (Magalhaes, Peleteiro et al. 2012). The truth behind
these conflicting studies is better understood by analyzing their underlying mechanisms.
Many of the lifestyle choices thought to help prevent breast cancer are either directly or
indirectly related to energy balance. Energy balance is most often described as calories consumed verses
those expended during physical activity (Hall, Heymsfield et al. 2012). For this reason, caloric intake and
physical exercise are among the energy balance lifestyle choices which may have the greatest potential
to reduce breast cancer risk. Other factors which are indirectly related to energy balance have also
shown some potential with regards to breast cancer prevention. Those factors include maintaining a
healthy diet of fruits and vegetables, moderate intake of red wine, and eating “good fats”. In the past it
has been unclear whether these factors have independent potential to reduce breast cancer rates, or
whether they are simply a means of controlling overall caloric intake, another possible prevention
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strategy. Rather than focusing on epidemiological studies, this review will focus on the underlying
mechanisms behind breast cancer prevention to more fully understand the science behind these
controversies.
Obesity
Traditionally, the most common indicator of energy balance is body mass index (BMI) which
estimates body fat using an individual’s height and weight. Obesity, as defined by a BMI greater than 30,
is a known risk factor for a variety of diseases including cancer. This is especially true for breast cancer in
which the proximity of the adipose tissue may have a direct influence on the tumor (Brown and Simpson
2012; Wang, Lehuede et al. 2012; Zhao, Sachs et al. 2012). Unfortunately, the evidence linking BMI and
breast cancer appears complex. For example, obesity during pre-teen years (ages 5-10) is inversely
related to breast cancer risk (Baer, Tworoger et al. 2010). On the other hand, obesity after menopause is
positively related to breast cancer incidence (Carmichael and Bates 2004; Lahmann, Hoffmann et al.
2004; Cheraghi, Poorolajal et al. 2012; Phipps, Buist et al. 2012; Xu, Sun et al. 2012). Although this is
fairly well established, the relationship between premenopausal obesity and breast cancer risk remains
less clear. The majority of studies report that obesity, before menopause, is inversely related to
premenopausal breast cancer (Carmichael and Bates 2004; Palmer, Adams-Campbell et al. 2007).
However, a few studies report either no association or a positive association with breast cancer (Eng,
Gammon et al. 2005; Cecchini, Costantino et al. 2012; Ogundiran, Huo et al. 2012). This complexity
warrants a discussion regarding the obesity-related signaling pathways.
One of the mechanisms by which obesity is now thought to contribute to breast cancer is
through the increased presence of leptin. Leptin is an adipose-tissue derived signaling molecule and is
overexpressed in breast cancer, particularly in high-grade tumors (Artac and Altundag 2011). Leptin
contributes to cancer proliferation through activation of the mitogen-activated protein kinase (MAPK)
and phosphatidylinositol 3-kinase (PI3K) signaling pathways as well as the JAK/STAT3 pathway
(Frankenberry, Skinner et al. 2006; McCormack, Schneider et al. 2011). These pathways are often
associated with tumor formation due to their involvement in cell proliferation and apoptosis.
Additionally, Valle et al. reported that leptin may also increase the mitogenic effects of estrogen through
the alteration of the estrogen receptor alpha and beta ratio (Valle, Sastre-Serra et al. 2011). This ratio
increased as a result of chronic exposure to leptin, which also enhanced estrogen-dependent
transcriptional activity and increased cell growth (Valle, Sastre-Serra et al. 2011). In addition to
activating cell proliferation, leptin also poses a risk to breast cancer patients through its ability to
influence epithelial to mesenchymal transition (EMT). Yan et al. demonstrated that leptin increases
beta-catenin levels which are essential for promoter recruitment which leads to leptin-induced EMT and
tumor formation. Beta-catenin levels are increased through leptin-induced phosphorylation of glycogen
synthase kinase 3 beta (GSK3 beta) by both activated Akt and by activation of Wnt signaling through
MTA1 (Yan, Avtanski et al. 2012).
Another obesity-related signaling pathway which may contribute to breast cancer is insulin-like
growth factors (IGFs), especially IGF-1. Obesity is known to increase circulating insulin and IGF-1 which
has been linked to tumor cell growth (Brown and Simpson 2012; D'Esposito, Passaretti et al. 2012).
Consequently, it plays a major role in obesity-related breast cancer. In fact, Creighton et al. analyzed the
transcription signature of primary breast tumors of obese patients compared to non-obese patient’s
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tumors. They reported a transcriptional signature of 662 genes in the obesity-associated tumors, most
of which were involved in IGF signaling (Creighton, Sada et al. 2012). This illustrates the importance of
the IGF signaling pathway in obesity-related breast cancer. Overall, IGF-1 has been linked with cell
survival (anti-apoptosis) in addition to tumor cell growth (Yu and Rohan 2000; Godsland 2010). This
occurs primarily through activation of PI3K/Akt and MAPK/p38 pathways (Sung, Yeon et al. 2011).
D’Esposito et al. reported IGF-1’s release from adipocytes can be regulated by the presence of glucose
and fatty acids such as palmitate or oleate (D'Esposito, Passaretti et al. 2012). IGF-1, IGF-2, and IGF-1
receptors (IGF-1R) have also been linked to estrogen (Mawson, Lai et al. 2005). For example, IGF-2 is
recognized by IGF-1R and activates both estrogen receptor-alpha and estrogen receptor-beta
(Richardson, Hamilton et al. 2011). Additionally, Song et al. demonstrated that estrogen can utilize
either the IGF-1R or the estrogen receptor (Song, Chen et al. 2010). These underlying mechanisms,
especially their link to estrogen, may help us better understand the controversy of premenopausal
obesity-related breast cancer.
Diet: Monounsaturated Fats and Olive Oil
Dietary choices and calorie reduction are lifestyle choices which may help lower the risk of
breast cancer (Omodei and Fontana 2011; Nogueira, Dunlap et al. 2012). The ‘Mediterranean diet’ and
its components have been investigated for their potential to reduce an individual’s risk for cancer. The
‘Mediterranean diet’ includes food generally consumed within this region including nuts, fruits,
vegetables, legumes, whole-wheat bread, fish, olive oil (OO) and red wine (Pauwels 2010). Within this
diet, olive oil appears to reduce breast cancer risk specifically (Tsuji, Tamai et al. 2012). Other aspects of
the ‘Mediterranean diet’ have beneficial properties and may protect against other types of cancer, but
are discussed thoroughly in other reviews (Egeberg, Olsen et al. 2009; Taylor, Misra et al. 2009; Kabat,
Cross et al. 2010; Alexander, Weed et al. 2011; Fortes and Boffetta 2011; Fu, Deming et al. 2011; Hardy
and Tollefsbol 2011; Hauner, Janni et al. 2011; Jansen, Robinson et al. 2011; Shanmugam, Kannaiyan et
al. 2011; Magalhaes, Peleteiro et al. 2012).
Olive oil has two major components which are studied in relation to breast cancer: the fatty-acid
component, especially oleic acid and the antioxidant component containing polyphenols. Several studies
have reported an inverse relationship between olive oil or other monounsaturated fats consumption
and breast cancer (Wolk, Bergstrom et al. 1998; Thiebaut, Kipnis et al. 2007; Psaltopoulou, Kosti et al.
2011; Tsuji, Tamai et al. 2012). There are also several studies which report either no or weak association
between monounsaturated fat and breast cancer (Sieri, Krogh et al. 2008; Zhang, Ho et al. 2011).
Therefore, it is imperative that we understand the mechanisms by which monounsaturated fats such as
olive oil influence breast cancer.
The underlying mechanism by which OO affects breast cancer is primarily through human EGFR
type 2 (HER2/neu) (Colomer, Lupu et al. 2008; Menendez, Vazquez-Martin et al. 2008; Menendez,
Vazquez-Martin et al. 2009). Since HER2-positive breast tumors are known to be more aggressive than
their counterparts, OO specifically protects against the more aggressive breast cancer tumors while
having only minimal or no effect on HER2-negative breast tumors (Colomer, Lupu et al. 2008). Early
work by Menendez et al. with breast cancer and HER2 demonstrated that the tumoricidal effects of OO
polyphenols are blocked when the HER2+ tyrosine activity is blocked, and OO is responsible for the
depletion of the HER2 protein (Menendez, Vazquez-Martin et al. 2008). This indicated that tyrosine
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kinase might play a major role in the mechanism of OO and HER2. Their follow-up study indicated that
OO polyphenols did not significantly decrease tyrosine kinase activity, but they did trigger more
apoptosis in HER2 over-expressing MCF10A cells. Additionally, they determined that despite the fact
that OO doesn’t regulate tyrosine kinase activity, the protective effects of OO specifically target breast
tumors which over-express the type 1 receptor tyrosine kinase HER2 (Menendez, Vazquez-Martin et al.
2009).
The polyphenols or antioxidant component of OO is also known for its ability to help protect
against DNA damage, thereby reducing the risk of breast cancer. Two of the major antioxidants that
have been studied in relation to breast cancer prevention are hydroxtyrosol and tyrosol. One recent
study demonstrated that hydroxtyrosol is a more potent antioxidant than tyrosol due to its ability to
lower the concentration of reactive oxygen species (ROS) in MCF10A cells more compared with tyrosol
(Warleta, Quesada et al. 2011). Furthermore, they also showed that hydroxtyrosol was able to prevent
oxidative DNA damage in three breast cancer cell lines while tyrosol did not.
Although polyphenols represent a major component of OO, other major components of OO are
also known to play a role in the protection against breast cancer. Specifically, the protective effect of
certain dietary fats has been linked to regulating the amount or activity of transcription factors. This is
especially true regarding OO and breast cancer. For example, Menendez et al. made the observation
that oleic acid found in OO is known to repress the transcriptional activity of the HER2 gene. They also
showed the HER2 promoter was essential for this repression and that oleic acid also up-regulates PEA3,
a transcriptional repressor of the HER2 gene (Menendez JA 2006). Mendendez el al. later found that
oleic acid also down-regulates the fatty acid synthase gene (FASN) which decreases the risk that
precursor lesions will become invasive (Menendez and Lupu 2006). Overall, it appears that OO has
potential to reduce the risk of breast cancer formation, especially of the more aggressive types including
HER2-positive and over-expressing FASN tumors.
Although most of the work involving breast cancer prevention and OO has been in vitro, there is
also in vivo evidence to support the protective effects conferred by OO. For example, Escrich et al.
determined that breast cancer-induced mice that were fed a diet rich in OO showed a slight protective
effect over mice that were fed a high-corn diet. Additionally, the tumors in mice fed with an OO-rich diet
were less aggressive, compared to controls (Escrich, Moral et al. 2011). Furthermore, OO led to
modifications in the tumors which corresponded with lower proliferation, higher apoptosis and lower
DNA damage, compared to control tumors. Costa et al. demonstrated that adenocarcinomas which
arose from rats fed a high-OO diet were of a lower histological grade compared with adenocarcinomas
from rats fed a high-corn diet. These high-OO diet adenocarcinomas were also associated with fewer
necrotic and invasive areas (Costa, Moral et al. 2004). Overall, it appears that OO as a source of
monounsaturated fat has the potential to decrease both breast cancer incidence rates as well as breast
cancer aggressiveness.
Physical Exercise
Physical exercise as a prevention strategy against cancer is most often associated with a means
of reducing the negative effects of obesity or in other words, energy imbalance. This may be one reason
why the connection between breast cancer prevention and physical exercise is less well established and
understood than other preventative strategies. However, new evidence has demonstrated that physical
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activity may confer breast cancer-specific protection beyond reducing obesity (Bernstein, Henderson et
al. 1994; Bernstein 2009; Shin, Matthews et al. 2009; Friedenreich, Woolcott et al. 2010; Morris, Jones
et al. 2010; Lynch, Neilson et al. 2011; Albrecht and Taylor 2012).
Recent evidence has indicated that physical exercise prevents breast cancer primarily through
its ability to reduce sex hormone levels in women. This mechanism is crucial since estrogens promote
the risk of breast cancer development due to the stimulation of mitosis and regulation of cell
proliferation. Friedenreich et al. sheds further light on this mechanism as it showed that physical
exercise initiated a significant decrease in estradiol and increase of sex-hormone binding globulin
(SHBG), with no significant impact on levels of estrone, androstenedione, and testosterone
(Friedenreich, Woolcott et al. 2010). Furthermore, Kossman et al. conducted a study involving seven
healthy premenopausal women at high risk for breast cancer resulted in a beneficial reduction of
estrogen (18.9%) and progesterone (23.7%) after 300 minutes of vigorous physical exercise per week for
seven menstrual cycles (Kossman, Williams et al. 2011). Despite these encouraging results, there
remains some controversy regarding the effect of exercise and hormone levels in premenopausal
women. For instance, in the 16-week WISER study, no significant differences in sex hormones or SHBG
were demonstrated between exercise and sedentary groups (Smith, Phipps et al. 2011). The results of
the study involving the high-risk premenopausal women may be due to the increased length of the
study, the performance of vigorous activity opposed to moderate exercise, or the doubled duration of
physical activity compared with the WISER study. Nonetheless, varied results were noted. One principle
behind many of these studies is the fact that an exposure to higher levels of sex hormones increases
breast cancer risk. Evidence for this claim is a study by Morris et al. which correlated an increased risk of
breast cancer with earlier onset of ovulation in young women who were not physically active and
underwent menarche at an earlier age (Morris, Jones et al. 2010). Overall, these studies demonstrate
that physical activity may play an important role in lowering breast cancer risk, through lowering the
levels of sex hormones, especially as a result of lifelong physical activity.
Conclusion
Several studies have demonstrated the importance of maintaining beneficial lifestyle choices
throughout an individual’s lifetime to reduce breast cancer risk (Bernstein, Henderson et al. 1994;
Hilakivi-Clarke, Andrade et al. 2010; Cabanes, Pastor-Barriuso et al. 2011; Escrich, Moral et al. 2011;
Lynch, Neilson et al. 2011; Kark, Goldberger et al. 2012). One possible explanation for this is that the
initial accumulation of driver mutations which have the potential to ultimately lead to malignancy, occur
in young adults. Unfortunately, few studies address this important issue. This may be a possible
explanation why some diet or physical exercise studies report insignificant correlations. Perhaps the
effect of these factors on breast cancer risk was not seen due to the limited time of the study, or that
the potentially beneficial agents could not reverse the effects of previous poor lifestyle choices. It may
be premature to disregard these factors without long-term studies which include young adults.
Overall, there are several lifestyle factors which appear to aid in breast cancer prevention.
Obesity is one factor which has shown a consistent and strong correlation with increased breast cancer
risk. Dietary choices, especially the type of fat consumed, and physical exercise have shown considerable
promise in reducing risk. Despite some conflicting epidemiological studies, it is clear that obesity, dietary
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fat, and physical exercise each have underlying mechanisms which may help protect against breast
cancer. A thorough understanding of these mechanisms will no doubt lead to the discovery of novel
targets and therapies which may extend the protective effects of these lifestyle choices.
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Summary
The diagnostic and prognostic significance of TK1 has been studied and validated since
the 1980’s. However, unforeseen challenges arose which barred TK1 from clinical use. Recent
advances have overcome these challenges which have propelled TK1 again into clinical view. In
this work, we validate the diagnostic and prognostic significance of TK1 using novel TK1
antibodies. We demonstrated that our antibodies are both sensitive and specific for TK1 in
malignancy and hope they will facilitate TK1’s clinical use.
Using a novel TK1 monoclonal antibody (CB001), we demonstrated that TK1 elevation
in breast cancer is an early event. TK1 was significantly elevated in breast carcinoma and breast
hyperplasia, a pre-malignant disease, compared to normal controls. Furthermore, we
demonstrated that TK1 may detect tumor cells in ‘normal’ tumor margins (considered normal
under current pathology standards), with an increased risk of progression. Some normal tumor
margins overexpressed TK1 while corresponding true normal tissue from noncancerous
individuals did not express TK1. Similar results were found with a variety of malignancies
including lung, prostate, colon, esophagus, stomach, liver, and kidney tissues. TK1 expression
increased with increasing grade of prostate cancer. Interestingly, the prostate hyperplasia tissue
in our study did not overexpress TK1. Since other studies have demonstrated that elevated TK1
is associated with risk of progression in pre-malignant tissue, perhaps the prostate hyperplasia
tissue in our studies did not have an increased risk of progression. We also demonstrated that
TK1 is overexpressed in true normal adrenal gland cells, germ cells of the testis, and
hematopoietic cells of the bone marrow. Overall, TK1 is significantly elevated in many of the
major types of malignancy and may be a useful early detection tool in these corresponding
cancers.
We also demonstrated a novel TK1 immunoassay which is sensitive and specific for early
stage lung cancer patients. TK1 is significantly elevated in the serum of patients with the earliest
stage lung cancer (pT1N0M0), stage 2 lung cancer and all lung cancer patients in this study,
compared to controls. The TK1 ELISA has a high specificity and sensitivity. TK1 is also
significantly elevated in sputum which may aid in developing a lung cancer specific early
detection screen. We hope this study can be applied to current high-throughput clinical
applications to facilitate TK1 has a clinical screening, diagnostic, and monitoring treatment tool.
In conclusion, TK1 is significantly elevated in the very early stages of the most common types of
malignancy. We hope this work will continue to propel TK1 forward into clinical view in the
coming years.
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Appendix: Unpublished data
Figure 1: Localization of TK1 and other salvage pathway enzymes in human cancer cells using immunogold labeling
transmission electron microscopy (TEM). A-E are as followed: TK1, APRT, dCK, HGPRT, Control.
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Figure 2: Prognostic significance of TK1 and Ki67 in breast cancer tumor tissue. TK1 is a better prognostic marker
than Ki67. TK1 is associated with time to recurrence but Ki67 was not associate with any patient outcome.

Our TK1/Ki67 study
• TMA (tissue microarray) with 300+ breast
cancer ptxs.
• Clinical data including: age, grade, stage, tumor
size, positive nodes, metastasis, ER, PR,
Her2neu, treatment, and patient outcome data.
• Average follow-up time was 5.9 years (longest
10.2 years).
• 3 patient outcomes: recurrence, time to
recurrence, and died of disease.
TK1

Tumor Grade
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Grade 1
Grade 2
Grade 3

58%

Ki67
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Manual vs Digital Scoring
Ki67

TK1

Ki67

TK1

Manual vs Digital Scoring
Manual TK1 scores

TK1 Positive Index
2%

23%

32%

0 (0-5%)

31%

0-20%
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1 (10-20%)
2 (>20%)
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Manual Ki67 scores
11%
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Ki67 Positive Index
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0 (0-5%)
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0-20%
21-50%
>50%

69%

TK1 and Ki67 correlate (p<.0001)
TK1 and grade correlate (p=.003)
TK1 and ER+ correlate (p=.0073)

No Correlations found between FAS, Annexin 1, PR,
Her2neu, age, diagnosis, stage, or type of treatment.
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Final Predictive Models
Died of Disease:

-Positive nodes (p=.016)
-PR (p=.0108)

+1 positive node=
9.8% incr chance of
cancer-related death
If PR NEG then 4.6x
incr chance of cancerrelated death

Recurrence:

-Positive nodes (p=.0433)
-Metastasis (p=.0262)
-Tumor size (p=.0416)

+1 positive node= 5.8%
incr chance of getting
recurrence.
No metastasis= 82.5%
less likely of getting
recurrence.
+1cm in tumor size=
10.3% incr chance of
getting recurrence.

Time to Recurrence:

-Positive nodes (p=.0376)
-Metastasis (p=.0348)
-Tumor size (p=.0794)
-TK1 (p=.0627)
+1 positive node: time to
recurrence is 0.04yr
sooner
No Metastasis: Ave 3.2yr
to recurrence
+1cm in tumor size: time
to recurrence is 0.07yr
sooner (baseline: 1.8yr)
0 TK1 score: add 0.99yr
before recurrence
1 TK1 score: add 0.6yr
before recurrence

Figure 3: Measuring TK1 autoantibodies in the serum of cancer patients. TK1 autoantibodies are detectable by
direct ELISA in the serum of cancer and healthy individuals.

Auto-antibodies to sTK1

Serums NO TCEP

Anti-Human abs
+ HRP
Anti-TK1 abs in
Serum

TK1
Serums ttx w/TCEP

*TK1-730kDa is inactive
and will dissociate with
reducing agents.

[DTT]
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Figure 4: TK1 Sandwich ELISA. There is a significant difference in TK1 levels between lung cancer and healthy
individuals. More samples are needed to confirm these findings.

Current Sandwich ELISA-Serum data

p value (2 tail) 0.015034
p value (1 tail) 0.007517

RED=Cancer
BLUE=Normal

Figure 5: TK1 Competitive ELISA. In addition to creating a Direct and Sandwich ELISA, we can also detect TK1 levels
using a competitive ELISA.
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Figure 6: Serum TK1 is not heavily glycosylated according to gel mobility assay after treatment with PNGase and
EndoH. Serum TK1 exists as a high molecular weight form (200-700 kDa) as detected by a native western blot.

Active secretion of TK1 by cancer cells?

PNGase F removes all types of N-linked
Endo H removes only high-mannose and
some hybrid types

Lysate Media RNAse B
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+

-
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No shift for TK1

Gel Mobility Shift Assay

Alternative approaches to Mobility Shift Assay
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Visualize TK1-730kDa in cancer serum

480kDa
–
200kDa

150kDa
100kDa
80kDa

60kDa
50kDa
40kDa

720kDa
480kDa
242kDa
146kDa
66kDa

20kDa

*The same bands
appear with TK1
abs that bind to
other epitopes.

Detailed Materials and Methods:
IRB Approval: All patient serum was collected and consented according to IRB approval at both
Brigham Young University and University of Colorado at Denver. No IRB approval was needed
for purchased tumor tissue specimens from Cybrdi. All other tumor tissue specimens were
collected according to IRB approval with Intermountain Healthcare.
Immunohistochemistry protocol:
A. Deparaffinization
1. Immerse array slides in xylene for 10min, repeat once in new xylene for 10 min.
2. Immerse array slides in 100% EtOH for 5 min.
3. Immerse in 95% EtOH for 5 min.
4. Immerse in 70% EtOH for 5 min.
5. Rinse array slides twice with PBS for 5 min each.
B. Antigen Retrieval (Heat-induced epitope retrieval)
1. Place deparaffinized sections in pre-boiled 0.01 M Sodium Citrate buffer (pH 6.0), keep
boiling for 12 min.
2. Take out the slides and allow the slides to cool to room temperature for 20 min.
C. IHC Staining
1. The endogenous peroxidase activity is blocked at room temperature by 20 min
in the final 3% H2O2 in Methyl Alcohol.
2. Rinse array slides in PBS for 5 min, 3 times.

incubation
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3. Apply the blocking 10% normal horse serum, incubate for 30 min at room temperature, and
throw off residual fluid.
4. Apply primary antibody at the predetermined dilution of 1:100 at room temperature for 3
hours.
5. Rinse array slides three times in 1 x PBS for 5 min each.
6. Incubate array slides with a biotin-conjugated secondary anti-mouse antibody (ABC Kit,
Vector Lab Inc.) at room temperature for 30 min.
7. Rinse array slides three times in 1x PBS for 5min each.
8. Incubate array slides with Streptavidin-Peroxidase (ABC Kit, Vector Lab Inc.) at room
temperature for 30 min.
9. Rinse array slide 3 times in 1x PBS for 5 min each.
10. Proceed DAB Detection Kit (Vector Lab Inc.), control the degree of staining under regular
microscope.
11. Wash array slides with tap water.
12. Stain and differentiate array slides in hematoxylin for 12 min.
13. Dehydration and transparency of array slides.
14. Mount cover slides on the array slides.
Western Blot (and Dot Blot) protocol:
10X Everything Buffer Recipe (2L):
60.6 g Tris base
288 g Glycine
Bring volume up to 2L with ddH2O (make sure you add some water before adding chemicals)
1X Native Running Buffer Recipe (1L)
100 mL Everything Buffer
Bring volume up to 1L with ddH2O
1X SDS-Page Running Buffer Recipe (1L)
100 mL Everything Buffer
Add 5 mL 10% SDS
Bring volume up to 1L with ddH2O
Laemmli 4X Denaturing Buffer (10mL)
4% SDS (0.8 g)
10% 2-Mercaptoethanol (1 mL)
20% glycerol (4 mL)
0.01% Bromophenol blue (0.00102 g)
0.125 M Tris HCl (2.4 mL of 1 M Tris HCl.)
2.8 mL ddH2O
Bring the pH to 6.8. Store at -20⁰C.
Laemmli 4X Native Buffer (10mL)
20% glycerol (4 mL)
0.01% Bromophenol blue (0.00102 g)
0.125 M Tris HCl (2.4 mL of 1 M Tris HCl.)
4.6 mL ddH2O
Bring the pH to 6.8. Store at -20⁰C.
1. Obtain your sample and mix it 1:1 with your laemmli buffer (Remember, denaturing for a
SDS-PAGE and native for a native gel!!!).
2. If you are running a SDS-PAGE, place your sample in boiling water for 5 min.
3. Select your polyacrlyamide gel according to your needs.
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4. Remove the bottom sticker from the gel casing (the electrophoresis will not work unless you
do so!).
5. Place the gel in the running box and fill box with running buffer.
6. Carefully remove the comb by pulling straight up. DO NOT allow the comb to twist as you
pull up!
7. Load your samples onto the gel (fill the gel wells with running buffer before samples).
8. Run the electrophoresis for 1 hour at 200 V (constant V) or until the blue leading bands reach
the bottom of the gel.
1X Transfer Buffer (2L) (Make in Walk-In Refrigerator with Cold Water)
200 mL Everything Buffer
200 mL Methanol
10 mL 10% SDS
Add ddH2O to 2L. DON’T CHANGE THE pH! (Keep cold until use)
**For native gels, don’t add the SDS.
1. While you gel has at least 30 min left, cut out a piece of PVDF membrane the size of the filter
paper.
2. Briefly (<5 min) soak your membrane in methanol.
3. Transfer your membrane to transfer buffer and let equilibrate for at least 30 min.
4. When your electrophoresis is finished, place one black filter pad on the left side of the
construction kit in cold transfer buffer.
5. Briefly soak one piece of filter paper by placing it on top of the black filter pad in cold transfer
buffer on the left side of the construction kit.
6. Carefully break open the gel casing and place the gel on top of the filter paper.
7. Place your cassette with the black side down on the right side of the construction kit.
8. Place your gel, filter paper, and black filter pad on the black side of the cassette, with the black
filter pad at the bottom.
9. Take your membrane and very carefully without touching the membrane as much as possible
place it on the gel.
10. Carefully roll out any air bubbles between the membrane and the gel.
11. Briefly soak another piece of filter paper and place it on top of the membrane.
12. Briefly soak another black filter pad and place it on top of the filter paper.
13. Close the cassette and place it in the transfer box black to black and red to red (or clear to
red).
14. Place an ice pack and a stirbar in the transfer box and fill with transfer buffer.
15. Place the transfer box on a stirplate and have the stirbar stir.
16. Run transfer at 50 V (constant V) for 2 hours in the back room of the refrigerator on the 7th
floor (across the hallway from the autoclave room). Do not let your transfer get to hot, as it could
destroy your membrane and proteins!
10X TBS (1L)
24.228 g Tris HCl
87.66 g NaCl
Fill up to 1L with ddH2O
TBS-T (1L)
100 mL 10X TBS
1 mL Tween-20
Fill up to 1L with ddH2O
5% Non Fat Dry Milk (NFDM) (50 mL)
2.5 g NFDM
Fill to 50 mL with 1X TBS
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1. Carefully remove the membrane from the cassette without touching it and check for the
presence of the molecular weight ladder.
2. Rinse once with TBS-T.
3. Block for 30 min with 5% NFDM.
4. Rinse 3 times with TBS-T for 5 min.
5. Prepare your 1⁰ antibody (see table on following page).
6. Cut membrane and place membranes in labeled plastic bags.
a. If using small plastic bags, use 5 mL 5% NFDM per bag.
b. If using large plastic bags, use 15 mL 5% NFDM per bag.
7. Fill plastic bags with antibody/milk mixture, and carefully roll out all air bubbles.
8. Incubate your blot with 1⁰ antibody overnight while shaking at 4⁰ C.
9. Rinse 3 times with TBS-T for 5 min.
10. Prepare your 2⁰ antibody (see specific tables below).
a. If using small plastic bags, use 5 mL 5% NFDM per bag.
b. If using large plastic bags, use 15 mL 5% NFDM per bag.
11. Fill plastic bags with antibody/milk mixture, and carefully roll out all air bubbles.
12. Incubate your blot with 2⁰ antibody for at least 2 hours (or longer) while shaking at 4⁰ C.
13. Rinse 5 times with TBS-T for 5 min.
14. If using a biotin-streptavidin system, incubate with your 3⁰ antibody as above.
15. For HRP system (not chemilluminescent), add enough TMB to uniformly cover the
membrane. Place in dark area for development for at least 20 minutes (usually longer).
16. Rinse with ddH2O and take pictures!
17. For other systems, follow the instructions of those systems.
NOTE: For chemilluminescence, double the wash times, and half the amount of 2⁰ concentration
(included in protocol packet).
Direct ELISA protocol
• Dilute serum in Carbonate buffer, pH 9.6, in serum dilutions starting at 1/2.
• Add 50ul diluted serum or other sample to clear 96-well plate (Thermo-Fisher).
• Incubate overnight in cold room, on shaker (70rpm, 16-17 hours).
• Allow plate to shake at same speed at room temperature for 30 minutes while Block is
prepared.
• Prepare Block as followed: 2% BSA in Pierce Protein-Free T20 (PBS) Blocking Buffer
(Thermo-Fisher) (i.e. 0.8g BSA in 40ml T20). Allow to sit on shaker with plate for at least 15
minutes.
• Dispense diluted serum by inverting and shaking 96-well plate.
• Using a multi-channel pipette add 300ul PBS to each well. Dispense by inverting and shaking.
• Repeat for a total of 4 washes. On the fourth wash, incubate with PBS for 4 minutes before
dispensing.
• Add 300ul Block to each well and incubate on shaker at room temperature for one hour.
• Dispense Block solution. Wash with PBS as discussed above for a total of 4 washes with a 4
minute incubation during the last wash.
• Add 50ul of conjugated primary TK1 antibody (10ug/ml) diluted in Block to each well.
Incubate on shaker at room temperature for one hour. All the TMB to warm to room temperature
during this last hour.
• Dispense primary antibody and wash and discussed before with a total of 4 washes with a 4
minute incubation during the last wash.
• Add 50ul of room temperature Ultra-TMB (Thermo-Fisher) to each well using a multi-channel
pipette. Incubate in the dark for 20 minutes at room temperature.
• Quench by adding 50ul of 2M Sulfuric Acid to each well using a multi-channel pipette.
• Read in HT Synergy Plate reader at 450nm.
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